

Journal of Materials Chemistry B

Materials for biology and medicine

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: S. Yang, Z. Li, S. Li, J. Zhang, J. Huang, J. Ren and X. Wu, *J. Mater. Chem. B*, 2025, DOI: 10.1039/D5TB01369K.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

Advances in drug delivery system based on liposome-composite hydrogel microspheres

Shuanghong Yang^a, Ze Li^b, Sicheng Li^b, Jinpeng Zhang^b, Jinjian Huang^{a, b *}, Jianan Ren^{a, b *},
Xiuwen Wu^{a, b *}

^a Jinling Clinical Medical College, Nanjing University of Chinese Medicine, 305 East Zhongshan Road, Nanjing 210002, P.R. China.

^b Research Institute of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, P.R. China.

* Correspondence to:

Jinjian Huang, Research Institute of General Surgery, Jinling Hospital, Affiliated to Nanjing University of Chinese Medicine, 305 East Zhongshan Road, Nanjing 210002, P.R. China. E-mail: jinjian_huang@seu.edu.cn;

Jianan Ren, Research Institute of General Surgery, Jinling Hospital, Affiliated to Nanjing University of Chinese Medicine, 305 East Zhongshan Road, Nanjing 210002, P.R. China. E-mail: Jiananr@nju.edu.cn;

Xiuwen Wu, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, 305 East Zhongshan Road, Nanjing 210002, P.R. China. E-mail: wuxiuwen@nju.edu.cn.



Abstract

Research on liposome-composite hydrogel microspheres (LHMs) drug delivery systems, primarily composed of drugs, liposomes, and hydrogels, has garnered growing scientific interest. LHMs exhibit biosafety, modifiability, a wide range of loaded drug categories (water-soluble or fat-soluble), controlled and sustainable drug releasing capability, and specific cell-targeted performance, which compensates for the shortcomings of conventional drug delivery methods due to the complementary advantages of liposome and hydrogel microspheres. In this review, we systematically analyze the existing literature on LHMs and provide a comprehensive overview of their preparation methods. Specifically, we detail the fabrication techniques for liposomes, including thin-film hydration, solvent injection, multiple emulsion, reverse-phase evaporation, gradient, freeze-drying, supercritical fluid, and microfluidic approaches, as well as the methodologies for LHMs, such as microfluidics, electrospraying, 3D printing, reverse-phase microemulsion, and physical adsorption. We also conclude the optimization approaches of entire LHMs properties when to combine liposomes and hydrogel microspheres. At last, we presented the applications and challenges of LHMs. We hope this review could foster more insights on LHMs in drug delivery fields.

Keywords: Liposome; liposome-composite hydrogel microspheres (LHMs); Drug delivery; Preparation methods



1. Introduction

To address the inherent limitations of conventional drugs, various drug delivery systems have been developed.¹⁻³ Despite these advancements, conventional drug delivery systems still encounter persistent challenges, such as the need to mitigate drug toxicity, prolong therapeutic efficacy, reduce dosing frequency, and enhance patient compliance.⁴⁻⁶ With continuous research on nanocomposite drug delivery systems, many limitations of drugs have been solved while giving some novel functions to the delivery systems.

In 1965, Bangham et al. pioneered the dispersion of phospholipids in water, leading to the discovery of spherical structures observed under electron microscopy, which were termed as “liposomes”. These structures primarily consist of a phospholipid bilayer forming spherical vesicles with an aqueous core.⁷ The amphiphilic nature of liposomes, arising from the hydrophilic head and hydrophobic tail of phospholipid molecules, enables the encapsulation of hydrophilic drugs within the aqueous core and lipid-soluble drugs within the bilayer.⁸ Despite their ability to encapsulate drugs and address certain pharmaceutical limitations, liposomes exhibit inherent drawbacks, such as the cytotoxicity of positively charged liposomes, rapid hepatic clearance, susceptibility to digestive enzymes, and instability.^{9, 10} These limitations have hindered the advancement of liposome-based drug delivery systems, prompting increasing research interest in the development of liposome-composite hydrogel delivery systems as a potential solution.

Hydrogels are three-dimensional polymeric networks characterized by their biodegradability and hydrophilicity. These materials exhibit exceptional water absorption and retention capacities, closely mimicking the natural extracellular matrix, thereby facilitating cellular growth and promoting the regeneration of damaged tissues.^{11, 12} Notably, their excellent biocompatibility and resistance to enzymatic degradation make them an optimal choice for gastrointestinal tract repair.¹³ The tunable porous structure of hydrogels provides a stable matrix for drug or cell encapsulation, effectively preventing rapid metabolic breakdown while enabling sustained and controlled release.¹⁴ Furthermore, the remarkable plasticity of hydrogels enables their application in advanced fabrication techniques, including three-dimensional (3D) /four-dimensional (4D) printing,¹⁵ microfluidics, and electrospinning into nano-microspheres.¹⁶ This versatility, combined with their intrinsic biomimetic properties, underscores their potential as a multifunctional platform for tissue engineering and drug delivery systems.



Drug delivery systems integrating liposomes with hydrogels have garnered significant attention owing to their unparalleled and synergistic properties.^{3, 17} This review focuses on recent advancements in LHMs drug delivery systems, which incorporate liposomes, hydrogels, and encapsulated therapeutic agents.^{17, 18} While liposomes offer substantial advantages as drug carriers, their inherent limitations, including rapid metabolic clearance *in vivo* and suboptimal stability *in vitro*, remain significant challenges.^{19, 20} In LHMs, hydrogels effectively address these limitations by enhancing stability and prolonging drug release, thereby expanding the therapeutic applications of liposomes while introducing novel functionalities.

LHMs demonstrate significant potential for diverse applications in medicine and biotechnology, offering substantial value in both research and clinical practice.^{21, 22} In this review, we systematically summarize the preparation methodologies of liposomes and LHMs, their performance optimization strategies, and their associated applications (Fig. 1A-D). Furthermore, we critically examine the current challenges and future perspectives of this advanced drug delivery system.






Fig. 1 Schematic illustration of the preparation methodology, optimization process, and applications of LHMs as drug delivery systems. (A) Methods for liposome preparation. (B) Construction of LHMs drug delivery systems. (C) Optimization of liposomal and hydrogel components in LHMs utilizing environmentally responsive materials. (D) Therapeutic applications of LHMs in preclinical disease models. (E) Formation process of unilamellar liposomes, including drug loading, small molecule-mediated targeted modification, and their fundamental structures. (F) Classification of Unilamellar Liposomes. IR 780, IR-780 iodide; COFs, Covalent Organic Frameworks; LAP, Lithium Phenyl(2,4,6-trimethylbenzoyl)phosphinate; PNIPAM, Poly(N-isopropylacrylamide); LHMs, liposome-composite hydrogel microspheres; SUVs, small unilamellar vesicles; LUVs, large unilamellar vesicles; GUVs, giant unilamellar vesicles. Created with Biorender.com.

2. Preparation of liposomes and LHMs

2.1 Preparation of liposomes

Liposomes are vesicular structures formed through the hydration of phospholipid molecules, which self-assemble in an aqueous phase to create bilayer structures.²³⁻²⁵ Liposomes are classified into unilamellar and multilamellar vesicles based on the number of lipid bilayers and the presence of a



shared aqueous core. Unilamellar vesicles, also termed as single-compartment liposomes, consist of a single phospholipid bilayer encapsulating an aqueous core. Their formation and modification processes are schematically illustrated in Fig 1E. These unilamellar systems are further subdivided into three categories based on size: (i) small unilamellar vesicles (SUVs, <100 nm), commonly referred to as nanoliposomes; (ii) large unilamellar vesicles (LUVs, 100 nm–1 μ m); and (iii) giant unilamellar vesicles (GUVs, >1 μ m), as shown in Fig 1F. Multilamellar vesicles (MLVs), in contrast, are characterized by multiple concentric phospholipid bilayers separated by aqueous compartments. Their size typically ranges from tens of nanometers to several micrometers, depending on the preparation method employed.^{19, 26, 27}

Liposomes are primarily composed of phospholipid molecules, with commonly used phospholipids including soy lecithin, egg lecithin, marine phospholipids, and milk phospholipids, among others.^{28, 29} The addition of cholesterol regulates the fluidity of the phospholipid bilayer membrane, reduces membrane permeability, protects phospholipids from oxidation, and promotes lipid chain accumulation and bilayer formation.^{30, 31} The preparation methods encompass traditional approaches such as thin-film hydration, solvent injection, multiple emulsions, reverse phase evaporation, gradient methods, and freeze-drying, as well as advanced technologies like supercritical fluid technology and microfluidic technology. Although numerous liposome-preparation strategies have been described, each methods inherent advantages and disadvantages (Table 1). Consequently, careful selection and judicious integration of these methods, tailored to the specific application context, are essential to maximize efficiency and achieve optimal outcomes.



118 **Table 1.** Advantages and disadvantages of liposome preparation methods

Methods	Advantages	Disadvantages
Thin-film hydration method	Simple, laboratory-scale; high EE for lipophilic drugs(EE $\approx$ 60–80 %)	Forms MLVs (1–5 μ m); low EE for hydrophilic drugs; requires post-homogenization
Solvent injection method	One-step; yields SUVs (<100 nm); ethanol or ether injectable	Dilution risk; residual organic solvent; limited lipid solubility in ethanol
Multiple emulsion method	High EE for hydrophilic drugs; scalable	Multi-step; residual solvent; broad size distribution
Reverse-phase evaporation	High EE for hydrophilic drugs; suitable for LUVs (100–1000 nm)	Residual solvent; protein/peptide inactivation risk; complex protocol
Gradient method	Active drug loading and high encapsulation rate	Sensitive to lipid type/size; requires precise pH/ion gradient
Freeze-drying method	Sterile, pyrogen-free product; long-term stable	Requires cryo-/lyo-protectants; high cost; multi-step process
Supercritical fluidics technology	Solvent-free; tunable size (100–150 nm); scalable	High equipment cost; critical parameter control (P, T)
Microfluidic technology	Monodisperse liposomes (20–100 nm, PDI <0.1); high throughput (>1 L h ⁻¹)	Channel clogging; high cost; requires flow-rate/temperature optimization

119 EE: encapsulation efficiency; MLVs: multilamellar vesicles; SUVs : small unilamellar vesicles; LUVs: large unilamellar vesicles; PDI: polydispersity index.

2.1.1 Thin-film hydration method

The thin-film hydration method is widely employed in laboratory settings for liposome preparation due to its operational simplicity.^{32,33} In this process, phospholipids, cholesterol, other lipid components, and the target drug are initially dissolved in an organic solvent system, typically comprising chloroform, methanol, and/or ethyl ether. Subsequently, a homogeneous lipid film is formed on the inner surface of a rotary evaporation flask through solvent removal under reduced pressure. Upon the addition of the aqueous-phase medium and subsequent rotation under controlled conditions, the lipid film undergoes hydration, resulting in liposome formation. While this method offers procedural simplicity, it is characterized by certain limitations, including heterogeneous particle size distribution and relatively low drug encapsulation efficiency.

In addition, the type of organic solvent, the type and proportion of surfactant, the cholesterol content, the time, and the temperature of mixing, etc. all affect the properties of liposomes.³⁴ For instance, the physical characteristics of liposomes demonstrate substantial dependence on the solvent system employed. Specifically, the utilization of a chloroform-ether binary solvent system tends to produce LUVs, whereas the application of pure chloroform often results in smaller multilamellar vesicles.³⁵

Mirveis et al.³⁶ developed a liposomal formulation by dissolving Soybean phosphatidylcholine, cholesterol, and DSPE-PEG2000 in chloroform at a molar ratio of 2:1:0.16. The organic solvent was completely evaporated at 45 °C and 120 rpm to form a homogeneous lipid film. Subsequently, the film was hydrated with arsenic trioxide-containing PBS for 20 minutes, followed by ultrasonication, 10 freeze-thaw cycles, and centrifugation. The resulting liposomes exhibited an encapsulation efficiency of $77.3 \pm 5.7\%$, a particle size of 108.0 nm, and a zeta potential of -2.95 mV. These liposomes were further functionalized by mixing with an anti-nucleolin aptamer solution, where the aptamer was immobilized on the liposome surface through either physical adsorption or chemical coupling. This functionalization imparted the liposomes with the ability to target nucleolin-overexpressing cancer cells. Moreover, the cytotoxicity of the aptamer-conjugated liposomes on the HT-29 cancer cell line was significantly reduced compared to arsenic trioxide treatment alone.

2.1.2 Solvent injection method

Solvent injection techniques, including ether and ethanol injection methods.³⁷ While sharing



similar operational principles, these methods are distinguished by the choice of organic solvent. In the ether injection approach, phospholipids, cholesterol, and the target drug are dissolved in ether. The resulting organic phase is then gradually introduced into preheated phosphate buffer (50–60°C) under continuous magnetic stirring. The subsequent evaporation of ether facilitates the formation of drug-loaded liposomes.³⁸ The ethanol injection method employs ethanol as the solvent, where the organic phase is injected into the aqueous phase to form liposomes. Residual ethanol contributes to drug stabilization and encapsulation. Although this method is operationally simple and achieves a relatively high encapsulation rate, it suffers from limitations such as slow preparation speed and incomplete solvent removal. As a result, it is primarily suitable for small-scale laboratory applications.^{39, 40}

Li et al.⁴¹ prepared a homogeneous mixture of yolk phosphatidylcholine, cholesterol, DSPE-PEG 2000, butyrate, and 4-octyl itaconate (4-OI) at a ratio of 100:25:60:50:10. The mixture was dissolved in ethanol to form a clear solution. This ethanolic solution was subsequently added dropwise into PBS buffer under continuous magnetic stirring, resulting in a 10% (v/v) ethanolic dispersion. The dispersion was then subjected to spinning and centrifugation at 12,000 rpm for 20 minutes, yielding liposomes with a mean particle size of 121.59 ± 0.29 nm and an encapsulation efficiency of $62.62 \pm 2.49\%$. As a pivotal metabolite in the tricarboxylic acid cycle, 4-OI demonstrates significant therapeutic potential by inhibiting the release of high mobility group box 1 protein and suppressing the expression of Gasdermin E N-terminal fragment-mediated cytokines.⁴² This compound specifically targets intestinal epithelial cells as an effective pyroptosis inhibitor, thereby preventing pyroptotic cell death in the intestinal epithelium. This protective mechanism facilitates mucosal repair in patients with ulcerative colitis, effectively reducing intestinal inflammation and promoting tissue integrity restoration⁴¹.

2.1.3 Multiple emulsion method

The multiple emulsion method is fundamentally based on the formation of a multi-layered emulsion system, achieved by dispersing a primary emulsion (commonly referred to as colostrum) within a distinct continuous phase. These systems are characterized as highly dispersed, as well as multi-phase structures with heterogeneous particle size distributions. Among the various types of multiple emulsions, the water-in-oil-in-water (W/O/W) and oil-in-water-in-oil configurations represent the two most prevalent and widely studied forms.^{43, 44}



The preparation process involves dissolving phospholipids and cholesterol in organic solvents, followed by their incorporation into the drug solution intended for encapsulation. This mixture is then emulsified to form a primary oil-in-water (O/W) emulsion. Subsequently, the primary emulsion is dispersed into a large volume of aqueous phase to create a W/O/W multiple emulsion system. Liposomes are ultimately obtained through organic solvent removal under controlled temperature conditions. This well-established technology has been successfully implemented in the production of marketed pharmaceutical products and demonstrates excellent scalability for industrial manufacturing.⁴⁵ Notably, liposomal cytarabine exemplifies the therapeutic advantages of this technology. As an effective treatment for lymphomatous meningitis, this formulation demonstrates enhanced therapeutic efficacy compared to conventional preparations. Through targeted modification, it reduces drug metabolism and degradation while improving pharmacokinetic properties, ultimately leading to reduced cytotoxicity and improved clinical outcomes.⁴⁶

2.1.4 Reverse-phase evaporation

The reverse-phase evaporation technique represents a widely utilized method for liposome preparation. In this process, lipids are initially dissolved in an organic solvent, which is subsequently brought into contact with an aqueous phase containing the target substance for encapsulation. The system's phase behavior varies depending on the organic solvent's miscibility with water: it forms a single-phase system when using water-miscible solvents (e.g., ethanol), or a two-phase system when employing water-immiscible solvents (e.g., diethyl ether). In the single-phase systems, phospholipid molecules disperse uniformly within the aqueous medium, whereas in biphasic systems, these molecules spontaneously arrange into a monolayer at the organic-aqueous interface.⁴⁷ The liposome formation process involves several sequential steps: first, water-in-oil (W/O) microemulsions are generated through ultrasonic treatment; second, organic solvents are eliminated using a rotary evaporator; and finally, phospholipid molecules reorganize into vesicular structures in aqueous medium. The resulting suspension is then passed through a polycarbonate filter membrane, yielding uniform monolamellar liposomes with controlled size distribution.⁴⁸

Liu et al.⁴⁹ utilized this approach to synthesize liposomes (nano-Pt/VP@MLipo) with a diameter of approximately 140 nm, a zeta potential of -16.7 mV, an encapsulation efficiency of 48.2%, and a drug loading capacity of 15% for platinum nanoparticles. By integrating mouse macrophage



membranes into the liposomal structure, they conferred biomimetic and targeting capabilities, which significantly reduced the inherent toxicity of nano-Pt. Furthermore, these engineered liposomes were designed to serve as catalytic oxygen suppliers, enhancing the efficacy of tumor photodynamic therapy. This innovative strategy resulted in substantial inhibition of invasive 4T1 tumor growth and pulmonary metastasis, while significantly prolonging the survival of the treated animals.

This versatile method is universally applicable to various lipids, lipid mixtures, and small molecules, demonstrating exceptional capabilities in encapsulating genes, organic solvent-resistant drugs, and water-soluble compounds. However, a notable limitation lies in the temperature requirements during the preparation process, particularly during ultrasonication and organic solvent evaporation under reduced pressure, which may potentially denature heat-sensitive substances.⁵⁰

2.1.5 Gradient method

The gradient method leverages the concentration or chemical nature differential between the interior and exterior of liposomes to facilitate drug encapsulation. Notably, this approach encompasses three established techniques: the pH gradient method⁵¹, acetate gradient method⁵² and ammonium sulfate gradient method⁵³. Among these, the pH gradient method involves preparing an internal buffer solution containing specific acidic components (e.g., citrate, tartaric acid), followed by adjusting the external pH of liposomes through techniques such as dialysis or column chromatography to approximate physiological pH, thereby establishing a pH gradient across the liposomal membrane.⁵⁴ Under controlled temperature conditions, the target drug is mixed with pre-formed blank liposomes possessing the established gradient. In this system, the drug exists in a lipophilic neutral form in the external neutral pH environment, enabling its passive diffusion across the lipid bilayer. Once inside the liposome aqueous phase, the drug undergoes protonation, converting to an ionic form that is effectively trapped within the liposomal core. This innovative process achieves efficient drug encapsulation. Furthermore, both the ammonium sulfate gradient method and calcium acetate gradient method operate on analogous principles for liposome preparation.

Hwang et al.⁵⁵ demonstrated that the encapsulation efficiency of liposomal diclofenac approached 100% when employing a calcium acetate gradient, while the pH gradient method yielded 5-50% encapsulation efficiency for FITC-insulin liposomes. This suggests that weakly acidic drugs can be effectively loaded into liposomes via an acetate gradient, whereas the pH gradient method is



particularly suitable for liposomal peptide preparation.

The nucleotide analogue dimeric aminobenzimidazole, a STING agonist,⁵⁶ faces challenges of low serum stability and poor cell membrane permeability. To address these issues, Zhang et al.⁵⁷ successfully encapsulated dimeric aminobenzimidazole in liposomes using the ammonium sulfate gradient method, achieving a particle size below 150 nm. This reduced particle size minimizes rapid clearance by the reticuloendothelial system, thereby extending its circulatory time in the bloodstream. Furthermore, the lower surface charge of these liposomes decreases nonspecific binding to plasma proteins, enhancing both circulation duration and cellular permeability.

2.1.6 Freeze-drying method

The freeze-drying method is utilized to produce heat-free and stable sub-micron liposomes.⁵⁸ In this process, lipids and water-soluble additives are initially incorporated into W/O emulsions, followed by freeze-drying. For instance, lipids and water-soluble carrier materials (e.g., sucrose) are dissolved in a tertiary butyl alcohol/water co-solvent system to form isotropic monolayers of liposomes. These are then filtered and sterilized using a sterile filter head, after which they are collected in freeze-drying containers. The resulting lyophilized product is subsequently rehydrated in an aqueous solution to generate a homogeneous suspension of liposomes.⁵⁹ Notably, the freeze-drying method enables drug loading at lower temperatures, significantly enhancing the storage stability of temperature-sensitive compounds, such as proteins, peptides, antibiotics, and vaccines.⁶⁰

Tanaka et al.⁶¹ employed this method to prepare mRNA-lipid nanoparticles by encapsulating *in vitro* transcribed messenger RNA (IVT-mRNA) into LNPs, thereby advancing mRNA-based therapeutic research. This approach addresses the challenges associated with IVT-mRNA, as it is susceptible to enzymatic degradation in extracellular fluids and its hydrophilic nature hinders efficient cell membrane penetration.⁶² To overcome these limitations, the researchers developed a “post-encapsulation” technique, which involves mixing the IVT-mRNA solution with lyophilized empty LNPs followed by brief heating. This strategy not only mitigates the inherent shortcomings of IVT-mRNA but also significantly extends its storage stability.

2.1.7 Supercritical fluidics technology

Supercritical fluidics (SCFs) have garnered significant attention as environmentally friendly



alternatives in the development of drug delivery systems. A schematic representation of SCFs is illustrated in Fig. 2A. SCFs exhibit unique physicochemical properties that combine the characteristics of both liquids and gases, including high density and gas-like low viscosity, which facilitates superior mass transfer efficiency.^{63, 64} Among various SCFs, carbon dioxide has emerged as the most extensively utilized supercritical fluid due to its cost-effectiveness, non-toxic nature, and relatively low critical pressure and temperature. The application of supercritical carbon dioxide as a non-toxic medium presents a viable alternative to conventional organic solvents in various pharmaceutical applications, particularly in drug particle engineering and nano-encapsulation technologies. These technologies include the supercritical anti-solvent process and the gas anti-solvent method.⁶⁵

Irinotecan, a semi-synthetic derivative of camptothecin, is primarily employed in the treatment of colorectal cancer and small cell lung cancer. However, its clinical utility is significantly limited by an extremely short half-life, necessitating continuous intravenous infusion to maintain therapeutic efficacy, which may lead to cumulative toxicity.⁶⁶ To address this limitation, Mohammadi et al.⁶⁷ developed polyethylene glycol (PEG)-modified liposomes encapsulating irinotecan hydrochloride using supercritical fluid technology. The hydrophilic and flexible properties of PEG chains effectively prevent phagocytic uptake. Moreover, PEG forms a polymer layer on the liposome surface, which enhances surface hydrophilicity and induces mutual repulsion between the polymer coating and blood components. This shielding of surface charge not only prolongs the circulation time of liposomes in the bloodstream but also indirectly extends the half-life of irinotecan hydrochloride. Compared to traditional methods, liposomes prepared using SCFs technology exhibit smaller sizes and higher encapsulation efficiencies, while also eliminating the need for hazardous solvents. This technology is not only easy to operate but also highly suitable for large-scale industrial applications and can be readily adapted to industrial GMP processes.^{67, 68}

2.1.8 Microfluidic technology

Microfluidic chips represent innovative instrumentation platforms widely used in synthetic chemistry and biology, commonly referred to as microfluidic reaction systems. This technology enables material synthesis by precisely controlling the flow of minute liquid volumes through micron-sized channels. By utilizing microfluidic devices, high pressures are converted into intense shear forces, facilitating the preparation of liposomes without the need for ultrasound or toxic chemicals.⁵⁹



Furthermore, this technology offers precise control over reaction conditions. When the Reynolds number within the microchannel is significantly below 1, the fluid flow is predominantly laminar, with inertial forces dominating. Under such conditions, fluid mixing primarily relies on the passive diffusion of molecules, resulting in rapid and efficient transfer of materials and heat. However, surfactants are often required to ensure smooth fluid flow and maintain stability, which may increase the risk of product contamination.⁷⁰

Gu et al.⁷¹ successfully synthesized baicalin-loaded liposomes using a microfluidic technique, achieving an exceptional encapsulation efficiency of $95.323 \pm 0.481\%$ and a uniform particle size distribution of 62.32 ± 0.42 nm. Compared to the free baicalin monomer, the fluorescence intensity of BCL-LPs in the zebrafish liver region exhibited a gradual decline as the concentration of Baicalin increased. This observation indicates a significant suppression in the expression of the proto-oncogene *krasv12*, further demonstrating the enhanced anti-tumor efficacy of baicalin-loaded liposomes in the zebrafish model.




Fig. 2 Construction of Liposomes and LHMs. (A) Schematic diagram of the Expansion Supercritical Fluid into an aqueous solution set up. (B) Schematic diagram of hydrogel microspheres fabrication process using microfluidics technology. (C) Schematic diagram illustrating the application of 3D printing technology in preparing drug delivery systems for LHMs. Created with Biorender.com.

2.2 Construction of LHMs drug delivery systems

Hydrogels are three-dimensional polymer networks characterized by their exceptionally high



water content (typically exceeding 90%) and serve as multifunctional platforms. Through structural and functional design, hydrogels have been successfully employed in a wide range of biomedical applications.⁷² However, when liposomes are utilized for drug loading, they encounter challenges such as limited drug-loading capacity, inadequate resistance to enzymatic degradation, and short storage stability.^{73, 74} These limitations can be effectively addressed by homogeneously dispersing liposomes within the prepolymer solution of a hydrogel. This approach not only enhances the drug-loading capacity, stability, and bioavailability of the drug *in vivo* but also imparts a degree of resistance to enzymatic degradation, reduces enzyme-induced damage, and enables dual-controlled release capabilities. Subsequently, the addition of a specific cross-linking agent under suitable conditions (e.g., temperature, pH, light) induces a reaction between the prepolymer and the cross-linking agent, leading to the rapid formation of a three-dimensional hydrogel network.^{3, 75, 76} Although the integration of liposomes and hydrogels confers dual sustained-release properties on the drug, there remains room for improvement in the delivery mode.

With the continuous advancement of hydrogel microsphere preparation technologies, a diverse range of LHMs has been developed to address various disease models. Compared to single liposomes, LHMs exhibit enhanced stability and drug delivery efficiency, significantly prolonging the duration of drug action. Their controlled and sustained drug release capability ensures prolonged therapeutic activity at the target site, thereby reducing the frequency of administration and improving patient compliance. As a tissue engineering scaffold, hydrogel not only promotes cell proliferation, differentiation, and migration but also exhibits excellent biocompatibility, thereby minimizing drug-induced damage to healthy tissues and improving treatment safety.⁷⁷⁻⁸⁰

The synthesis strategies of LHMs primarily encompass microfluidics, electrospraying, 3D printing, and the reversed-phase microemulsion method. Microfluidic technology enables high-precision preparation by generating uniform droplets, making it particularly suitable for constructing complex structures with targeting functionalities. Electrospray technology utilizes high-voltage static electricity to atomize liquid into microspheres, which is advantageous for drug loading and sustained-release applications. 3D printing offers the capability for personalized manufacturing, although it is associated with relatively high equipment costs. The reversed-phase microemulsion method involves the inversion of oil-water phases to form nanoscale vesicle cells which exhibit excellent stability and controllability. Each of these methods presents distinct advantages and limitations. Therefore, in



practical applications, the selection of an appropriate technical route should be based on specific requirements and objectives.

2.2.1 Microfluidics

Microfluidics is a cutting-edge technique that enables precise manipulation of fluids within micron-sized channel systems. By accurately regulating flow rates, this method facilitates the generation of droplets with uniform particle sizes and excellent dispersion. Subsequently, these droplets can be cured or polymerized to form microspheres through techniques such as ultraviolet (UV) curing or the addition of cross-linking agents.^{75, 81, 82} A schematic diagram illustrating the preparation of microspheres using microfluidics is presented in Fig. 2B. This approach offers precise control over the particle size, shape, and surface properties of the microspheres, ensuring a highly controllable and reproducible preparation process. Consequently, microfluidics is particularly suitable for fabricating LHMs (liquid-core microcapsules) with complex structures (e.g., core-shell configurations) and diverse functionalities.^{83, 84}

Li et al.⁷⁶ engineered liposomes by incorporating chondrogenic affinity peptides, which specifically target chondrocytes, thereby endowing the liposomes with active chondrocyte-targeting capabilities. In their subsequent experiments, the researchers developed LHMs through a multi-step process: first, the modified liposomes were combined with methacrylated hyaluronic acid; second, oil-in-water droplets were generated using microfluidics; and finally, the droplets were cross-linked and cured under UV light. As depicted in Fig. 3, this methodology outlines the construction of the LHMs drug delivery systems. In this framework, methacrylated hyaluronic acid serves as a drug reservoir, leveraging its porous structure to not only enhance the loading capacity of the mitochondrial autophagy activator, urocortin A, but also to facilitate controlled drug release.





Fig. 3 Construction of mitochondria dynamically oriented hydrogel microspheres. (A) Liposomes loaded with UA and modified by WY (WY-Lip/UA). (B) Application of microfluidics to construct drug-loaded liposome composite hydrogel microspheres (HM@WY-Lip/UA). UA, urocorin A; WY, WYRGRL. ⁷⁶, Copyright 2024. Reproduced with permission from Science and Technology Review Publishing House.

2.2.2 Electrospraying

Electrospraying is an advanced technique utilizing electrostatic forces to fabricate nanoparticles.^{85, 86} In this process, a drug-polymer solution is ejected through a magnetically charged nozzle into a collector. As the solution reaches the collector, the solvent evaporates, leaving behind dry nanoparticles. The underlying mechanism can be summarized in three key steps: first, the drug-polymer solution is introduced through a charged nozzle; second, an electric field is established by applying a voltage between the nozzle and the collector; and third, under the influence of the electric field, the solution is atomized into fine droplets, which solidify into dry nanoparticles (typically <200 nm in size) upon solvent evaporation during their trajectory toward the collector.⁸⁷

The characteristics of the resulting nanoparticles, including size and morphology, are influenced by various electrospray parameters, such as applied voltage, flow rate, nozzle-to-collector distance, solvent type, and the properties of the polymer solution (e.g., type, viscosity, and electrical conductivity). By optimizing these parameters, particularly voltage and flow rate, researchers can precisely control microsphere particle size and encapsulation efficiency. However, despite its advantages, electrospraying presents several limitations, including high equipment costs, operational complexity, stringent material requirements, low production yield due to its slow preparation process,

and safety concerns arising from the use of highly volatile solvents, which may also contribute to environmental contamination.⁸⁸

Strasdat et al.⁸⁹ developed fluorescent drug-loaded microspheres using two distinct techniques: the electrostatic dropping method and the electrospray method. These methodologies were employed to investigate the release characteristics of lipophilic drugs within hydrogel microspheres. In the electrostatic dropping approach, fluorescent drug-encapsulated liposomes were combined with a 1% sodium alginate solution. The mixture was subsequently crosslinked and solidified by introducing it dropwise into a continuously stirred CaCl_2 solution. This process was conducted under a constant 5 kV electrostatic potential for 30 minutes. Conversely, the electrospray method involved atomizing the mixture directly into the CaCl_2 solution to form microspheres. The experimental results demonstrated significant variability in drug transfer rates, with larger microspheres ($\sim 330\text{--}1360\ \mu\text{m}$) exhibiting prolonged transfer durations (24–57 minutes), while smaller beads ($<50\ \mu\text{m}$) showed accelerated transfer kinetics (~ 1.4 minutes).

2.2.3 3D printing

The primary methods for 3D printing LHMs encompass light-curing techniques (e.g., Stereo Lithography Apparatus and Digital Light Processing), inkjet printing, and extrusion-based approaches (e.g., Direct Ink Writing and Fused Deposition Modeling). Light-curing printing^{90, 91} offers superior resolution, typically achieving micron-scale precision, and enables the fabrication of complex geometrical structures. Nevertheless, this technique is constrained by several factors: the uniformity of the light source affecting print accuracy, limited resolution capabilities, elevated equipment costs that hinder large-scale production, and the necessity for specialized operational expertise. Huang et al.⁹² utilized digital light processing technology, a light-curing 3D printing method, to develop a digital light processing printing platform based on a full peptide hydrogel. By optimizing critical parameters such as blue light exposure time and layer thickness, they achieved the fabrication of complex structures, including hexagonal petals, microporous scaffolds, and ear models. The printing process exhibited a resolution of 0.5 mm and an error range within 0.122 mm, demonstrating high efficiency and accuracy in 3D structure fabrication.

Inkjet printing⁹³ demonstrates high resolution and flexibility, making it particularly suitable for fabricating intricate two- or three-dimensional structures. However, material viscosity constraints can



lead to nozzle clogging issues, necessitating frequent maintenance and cleaning procedures. Extrusion printing,⁹⁴ while being a well-established technology with comparatively lower equipment costs, exhibits reduced molding accuracy relative to light-curing techniques, typically operating at speeds between 0.1-0.2 mm/s. Notably, this method enables the fabrication of LHMs with sophisticated internal structures and functional complexities (Fig. 2C).

3D printing of LHMs represents an advanced fabrication technology that involves multiple critical steps. Initially, a hydrogel precursor solution incorporating liposomes must be prepared, typically comprising hydrogel materials, liposomes, and various biologically active components. This hybrid solution is subsequently subjected to layer-by-layer deposition using 3D printing technology, where precise control is maintained under specific environmental conditions, including temperature regulation, light intensity, and chemical cross-linking agents, to achieve desired geometric configurations and structural features. The principal advantages of this technology include precise modulation of drug or bioactive molecule release kinetics and spatial distribution while preserving their biological efficacy. Furthermore, 3D printing facilitates personalized medicine through the customization of implants or dressings tailored to specific anatomical shapes and functional requirements.^{95, 96}

Eugster et al.⁹⁷ employed 3D printing technology to fabricate injectable LHMs, designed for the localized treatment of abdominal peritoneal diseases, including peritoneal carcinomatosis, postoperative adhesions, and peritoneal fibrosis. Furthermore, the study developed a sustained-release 3D-printed composite system incorporating the tyrosine kinase inhibitor gefitinib. This innovative approach aimed to address the pharmacokinetic challenges associated with gefitinib, such as its rapid systemic clearance and limitations in intraperitoneal administration, thereby enhancing its therapeutic efficacy.

2.2.4 Reverse microemulsion method

The reverse microemulsion method involves inverting the aqueous and oil phases, rendering the aqueous phase continuous while dispersing the oil phase.⁹⁸ The resulting microemulsions are encapsulated with surfactants, forming nanoscale vesicular pools. The dispersion of these vesicles in the oil phase indicates the formation of O/W microemulsions. Microemulsions typically consist of four components: a surfactant, a co-surfactant, an aqueous phase and an oil phase. They have smaller



particle size and larger specific surface area, as well as superior stability, controllability and tunability.^{99, 100}

Wang et al.¹⁰¹ utilized this method to fabricate LHMs incorporating haemagglutinating factors, offering an alternative to traditional dressings by promoting rapid hemostasis and enhancing wound healing. In their study, sodium alginate and silk peptide served as the aqueous phase, while Ca^{2+} was employed as the cross-linking agent. By modulating the silk peptide concentration, the microspheres exhibited a remarkable water absorption rate of 1050% and a pore size of 19.59 nm.

2.2.5 Physical adsorption

Physical adsorption method, as the name implies, involves the adsorption of drug-loaded liposomes onto hydrogel microspheres. Although this method is straightforward and easy to implement, its drug release kinetics and resistance to enzymatic degradation remain inferior compared to microspheres fabricated through homogeneous mixing. In a related study, Han et al.¹⁰² developed a 3D-printed porous bioceramic scaffold (β -TCP) inspired by the “lotus seedpod” structure, which was integrated with liposomal hydrogel microspheres loaded with desferrioxamine (DFO) to accelerate bone defect repair. The GelMA microspheres and DFO liposomes were prepared using the microfluidic technique and the inverse evaporation heating method, respectively. Subsequently, DFO liposomes were adsorbed onto GelMA microspheres to form GML composite microspheres, which were then injected into β -TCP scaffolds. Follow-up studies revealed that this composite scaffold not only enhanced the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) but also exhibited significant angiogenic potential.

In summary, each fabrication strategy exhibits distinct merits and constraints. Microfluidic and electrospraying techniques enable the reproducible preparation of monodisperse microspheres with sub-micron precision; however, their elevated equipment costs and limited scalability impede routine large-scale production. 3D printing technology can realize personalized manufacturing of complex structures, but the equipment and technical threshold is high; The reverse phase microemulsion method has good controllability and stability, but the process is complicated and may involve organic solvents; Finally, the physical adsorption method is simple to operate, but the performance is relatively poor.



3. Performance optimisation of LHMs drug delivery systems

3.1 Selection of materials, concentrations and preparation conditions on LHMs

The selection of constituent materials, optimization of concentrations, and manipulation of preparation conditions are pivotal factors that markedly influence the drug-loading efficiency of LHMs delivery systems. Among these parameters, the judicious selection of phospholipid species plays a decisive role in determining liposomal stability, membrane fluidity, and permeability characteristics. Furthermore, precise adjustment of membrane material concentration and strategic modifications significantly impact the physical properties of lipid membranes, consequently affecting the particle size distribution and colloidal stability of liposomes.²⁹ Regarding the hydrogel matrix in LHMs drug delivery systems, the choice of synthetic material exerts profound effects on both drug release kinetics and biocompatibility profiles. Therefore, a comprehensive evaluation of material properties - encompassing biosafety, water absorption capacity, chemical stability, physical resilience, and biocompatibility - is imperative during the selection process.^{103, 104}

3.1.1 Factors affecting liposomes synthesis

The phospholipids used in synthetic liposomes fall into two main categories: natural phospholipids and synthetic phospholipids. Natural phospholipids are mainly represented by lecithin (phosphatidylcholine (PC)), which is primarily derived from egg yolk, and soya beans, and is neutral in nature; synthetic phospholipids mainly include DPPC (dipalmitoylphosphatidylcholine), DPPE (dipalmitoylphosphatidylethanolamine), and DSPC (distearylphosphatidylcholine), which are famous for their strong stability, high antioxidant property, and good stability of finished products.¹⁰⁵

Cholesterol and phospholipids constitute the fundamental structural components of liposomes and play a pivotal role in modulating membrane fluidity, thus serving as a “fluidity buffer” for the liposomal system. Notably, various wall materials exhibit distinct effects on liposomal encapsulation efficiency.³¹ For instance, Gładkowski et al.¹⁰⁶ demonstrated that liposomes incorporating soy sterols exhibited markedly enhanced rigidity and elevated phase transition temperatures in their hydrophobic regions compared to cholesterol-containing formulations. However, excessive cholesterol proportions may compromise liposome integrity. Elevated cholesterol content reduces phospholipid concentration, leading to impaired membrane formation, reduced structural stability, and increased susceptibility to membrane damage. Comparative studies using phytosterols - structurally analogous to cholesterol



(e.g., leguminous stanols, β -sitosterol) - revealed superior encapsulation efficiency in identical formulations compared to cholesterol-based systems.¹⁰⁷

Furthermore, the incorporation of auxiliary wall materials, specifically Tween 80, resulted in a notable reduction in particle size as the concentration of Tween 80 increased. This reduction was accompanied by a significant enhancement in the embedding efficiency of liposomes.¹⁰⁸ Additionally, the surface modification of liposomes using hydrophilic polymers, such as PEG, has been demonstrated to extend the retention time of liposomes within the circulatory system. This modification also minimizes the recognition and subsequent clearance of liposomes by the mononuclear phagocyte system.^{109, 110} Moreover, the composition and concentration of the hydrogel microsphere matrix play a crucial role in influencing both the drug release rate and the biocompatibility of the system.

3.1.2 Factors affecting hydrogel synthesis in LHMs

Selection of different hydrogel matrices (e.g., chitosan, gelatin, alginate, and GelMA, etc.) and application of different concentrations will affect the degree of cross-linking, swelling, and biodegradability of the hydrogel, which in turn will influence the drug release characteristics.¹¹¹ Specifically, the concentration of the hydrogel matrix determines both the cross-linking density and mechanical strength of the hydrogel. A high concentration may result in excessive density, impairing drug release and cell permeation. Conversely, a low concentration may lead to insufficient mechanical strength, compromising the effective immobilization of liposomes.³

Preparation conditions, such as temperature, pH, and cross-linking agents, play a critical role in determining the structure and properties of liposome composite hydrogel microspheres. For instance, temperature directly influences both the stability of liposomes and the cross-linking degree of hydrogels during preparation. Variations in pH can alter the charge state and stability of liposomes, as well as the solubility and degradation behavior of hydrogels.¹⁷ Furthermore, by adjusting the type or concentration of hydrogel cross-linking agents, the cross-linking density of hydrogel microspheres can be optimized. This optimization not only enhances their mechanical strength and water absorption properties but also increases drug loading capacity to a certain extent.¹¹²

Both liposome and hydrogel microsphere surfaces can be functionalized with specific antigens, antibodies, or ligands to achieve active or passive targeted drug delivery.¹¹³ Such targeted



modifications facilitate precise drug delivery, minimize toxic side effects, and enhance therapeutic efficiency.¹¹⁴ Depending on their solubility, drugs can be categorized as either water-soluble or fat-soluble. Water-soluble drugs are encapsulated within the aqueous core of liposomes, while fat-soluble drugs are embedded within the lipid bilayer or adsorbed onto the liposome surface.¹¹⁵

The preparation process of LHMs typically involves two sequential stages. Initially, drug-loaded liposomes are fabricated and subsequently modified to incorporate specific functionalities, including targeting capabilities and environmental responsiveness. In the subsequent stage, the prepared liposomes are integrated with a hydrogel matrix to form composite-structured microspheres. We have systematically reviewed and summarized recent advancements in the development of LHMs drug delivery systems, as comprehensively tabulated in Table 2.





542 **Table 2.** Drug delivery system for LHMs

number	Christen	Method	Liposome			Hydrogel			Study type	Applications	Ref
			Structure	Size (nm)	Payload	Structure	Size (μm)	Function			
1	ChsMA@Lipo	Electrospraying	HSPC, mPEG2000-DSPE, Cholesterol	122.3 ± 56.5	liquiritin	ChsMA, Chs, Sodium alginate	220 ± 61	Controlled-release	<i>In vitro</i> (Chondrocytes)	Osteoarthritis	22
2	MELs	Reverse-phase evaporation	PC, Cholesterol, DPPC	50 – 800	HBsAg	poly(L-lysine), alginate	400.00	Controlled-release, Protection	<i>In vivo</i> (HBsAg immunised mice)	Vaccine delivery	78
3	PPD-Lipo@HMs	Microfluidics	HSPC, egg yolk lecithin	118.50 ± 2.24	20(S)-protopanaxadiol (PPD)	Chinese herbal Bletilla striata polysaccharide	332.35 ± 22.24	Controlled-release , Microenvironment response	<i>In vitro</i> (RAW264.7)	diabetic wound tissue repair	83
4	RAPA@Lipo@HMs	Microfluidics	HSPC, Cholesterol, octadecylamine	102.3 ± 35.2	rapamycin (RAPA)	methacrylated hyaluronic acid	-	Controlled-release, Protection	<i>In vitro</i> (C-28/I2 cells)	Osteoarthritis	116
5	GEF-loaded liposome gel beads	3D printing	S80, DPPC	-	Gefitinib (GEF)	Sodium alginate	S80: 686 ± 49 DPPC: 712 ± 43	Controlled-release, Biological adaptation	<i>In vitro</i> (Huh-7 cells)	intraperitoneal(IP) administration	97
6	GM@PDA@Lipo-Ebselen	Microfluidics	Cholesterol, lecithin	141 .00 ± 20	Ebselen	Gelatin,methacrylic anhydride,polydopamine	GelMA - microspheres: 96 ± 7 PDA-grafted: 97 ± 8	Controlled-release, Adhesion	<i>In vivo</i> (outer hair cells) <i>In vitro</i> (HEI-OC1 cells)	Treatment of hearing impairment	117
7	ChSMA-RGD microspheres	Microfluidics	HSPC,DOPE, Cholesterol, octadecylamine	177.74 ± 11.95	TGF-β1	ChsMA, LAP, EFL	117.85 ± 24.16	Physical lubrication, mechanical protection	<i>In vitro</i> (BMSCs ,M1)	Osteoarthritis	118

8	Cur-R-CCMBs	Coacervation/extrusion/precipitation	Phospholipids, rhamnolipids	116.00 ± 70	curcumin	Chitosan, κ-carrageenan	-	Controlled-release	<i>In vivo</i> (male BALB/cmice)	Chronic wound infections caused by drug-resistant pathogens	119
9	A-Lipo/PAHM	Microfluidics	Cholesterol, lecithin	102.3 ± 0.7	ABT263	hyaluronic acid, methacrylic anhydride	200.6 ± 16.6	Targeted , Controlled-release , Promoting repair	<i>In vivo</i> (BMSCs,BMDMs)	osteoarthritis	120
10	AST NSC/HSA-PEG Liposomes @SA/CMCS Microspheres	Physical cross-linking	Cholesterol, lecithin, NSC, HSA, AST	83.00	Astaxanthin (AST)	SA,CMCS	-	pH responsive , controlled release	<i>In vitro</i> (Caco-2 cells,HepG2 cells)	hypercholesterolemia	121
11	E7-Lipo@Alg/Cs	Gas microfluidics	E7-peptide, ecithin, DSPE-PEG2K-NHS	152.98 ± 1.54	Fisetin	alginate, chitosan	320 ± 11.0	Targeted , Protection , Controlled-release	<i>In vitro</i> (BMSCs)	osteoporosis	122

3.2 Environmental response characteristics

To confer personalized environmental response properties to LHMs, the modification of either liposomes or hydrogel microspheres becomes imperative. Here, we delineate various modification techniques applied to these components, ensuring that the entire delivery system acquires specific environmentally responsive characteristics.




Fig. 4 Environmentally responsive modification of liposomes or hydrogels in LHMs. (A) Schematic illustration of the mechanisms underlying heat-triggered content release from liposomes with distinct lipid compositions. In TSP-modified liposomes containing DOPE, the thermal behavior of TSP-



modified liposomes is governed by the thermal activity of the temperature-sensitive polymers (TSP). The phase transition of TSP exerts structural pressure on the liposome membrane, inducing a transition from a bilayer to a hexagonal phase and ultimately leading to liposome disintegration. TSP, temperature-sensitive polymers; TSL, temperature-sensitive liposomes; T_c, transition temperature; LCST, Lower Critical Solution Temperature; HT, hyperthermia.¹²³, Reproduced with permission. Copyright 2022, Elsevier B.V. (B) Phase transition of temperature-sensitive hydrogels at room temperature and 37 °C.¹²⁴, Copyright 2020. Reproduced with permission from Wiley. (C) The TEM image of DHA-MLPs NPs.¹²⁵, DHA, dihydroartemisinin. Copyright 2016. Reproduced with permission from Elsevier B.V. (D) Schematic illustration for preparing the composite CMC microsphere containing poly(NIPAAm) and MNP. CMC, carboxymethyl chitosan; MNP, Magnetite nanoparticle, APS, diammonium peroxodisulphate.¹²⁶, Copyright 2018. Reproduced with permission from Elsevier B.V. (E) Schematic representation of PS5-DoxL preparation and its targeting mechanism.¹²⁷, Copyright 2022. Reproduced with permission from Elsevier B.V. (F) Schematic representation of RC microsphere pH responsiveness. RC: rotameric cross-linker.¹²⁸, Copyright 2017. Reproduced with permission from Wiley.

3.2.1 Temperature sensitive

Temperature-sensitive modification of liposomes is mainly achieved by both post-insertion and addition of temperature-sensitive polymers (TSP) to the organic phase, where the TSP is immobilised by the addition of lipid-soluble anchoring units for thermally triggered release of the drug at a specific temperature (Fig. 4A). Post-insertion method: the polymer is inserted into pre-formed liposomes, this method is convenient and fast but is limited to the outer surface of the liposome containing TSP, this method allows the drug to enter the liposome by remote loading but the presence of TSP may limit the remote loading of the drug as this usually requires heat. Addition of TSP to the Organic Phase: If TSP is soluble in the organic phase, it can be added to the lipid mixture, this approach allows the polymer to modify both the inner and outer surfaces of the liposome, resulting in a sharper and more intense thermally triggered release at the polymer's Lower Critical Solution Temperature (LCST).¹²³

Fu et al.¹²⁹ developed a temperature-sensitive liposomal nano-inducer, NIL-IM-Lip, which was modified with the photothermal agent IR 780 and loaded with the IDO 1 inhibitor 1-MT. This innovative system was designed to activate photothermal therapy, thereby inducing an immunogenic cell death effect. Simultaneously, the encapsulated 1-MT was utilized to modulate the tumour lymph node immune microenvironment by alleviating Treg inhibition and reversing the immunosuppressive environment. Additionally, 1-MT contributed to the activation of T cells and NK cells, promoting the remodelling of the tumour lymph node immune microenvironment. This dual-action approach significantly enhanced the efficacy of tumour immunotherapy by synergistically combining



587 photothermal therapy and immune modulation.

588 Temperature-sensitive modification of hydrogels initiates with the judicious selection of
589 monomers and polymers.¹³⁰ Notably, pNiPAAm has emerged as one of the most extensively
590 investigated temperature-sensitive systems, exhibiting a LCST at approximately 32 °C. To engineer
591 hydrogels with desired properties, hydrophilic or hydrophobic monomers are incorporated into the
592 polymer matrix through either chemical or physical cross-linking methodologies, thereby forming a
593 three-dimensional cross-linked network. The modulation of the polymer's LCST allows for precise
594 control over the hydrogel's hydrophilicity and its responsiveness to thermal stimuli. In a seminal study
595 conducted by Zhao et al.¹²⁴, a biodegradable triblock copolymer, PLLA-PEG-PNIPAm, was
596 meticulously designed and synthesized. This advanced polymer was subsequently employed to
597 fabricate nanofiber-based temperature-responsive gel microspheres through self-assembly,
598 specifically targeting cardiac regeneration. The unique property of this polymer lies in its ability to
599 exhibit liquid-like characteristics at ambient temperature, while rapidly transforming into a stable
600 three-dimensional hydrogel matrix under physiological conditions. Post-transplantation, nanofiber-
601 based temperature-responsive gel microspheres significantly enhanced cardiomyocyte survival and
602 improved functional cardiac recovery (Fig. 4B).

603 3.2.2 Magnetic sensitive

604 Magnetic materials with particle sizes ranging from 10 to 20 µm have been successfully
605 integrated into liposomes through various methods, including physical encapsulation¹³¹, chemical
606 coupling,¹³² embedding¹³³ and co-precipitation.¹³⁴ These materials encompass monomers (e.g., pure
607 iron, cobalt, nickel), alloys (e.g., iron-nickel alloys, iron-aluminium alloys), oxides (e.g., Fe₃O₄, FeO,
608 Fe₂O₃, MO, BaO), and hybrid magnetic materials. The incorporation of these magnetic components
609 endows liposomes with targeting and localization capabilities under the influence of external magnetic
610 fields.^{18, 131, 134, 135}

611 Li et al.¹²⁵ developed an innovative synthesis of magnetic dihydroartemisinin nanoliposomes
612 (DHA-MLPs) through an optimized thin-film dispersion-sonication technique. This novel formulation
613 ingeniously combines Fe₃O₄ nanoparticles with dihydroartemisinin (DHA), demonstrating
614 remarkable anticancer efficacy (Fig. 4C). The synthesized DHA-MLPs exhibited an average particle
615 size of 209.10 ± 4.92 nm, a zeta potential of -37.13 ± 1.01 mV, and a high drug encapsulation



efficiency of $82.12 \pm 0.91\%$. Additionally, the saturation magnetization strength (Ms) was measured to be 11.84 emu/g at room temperature. The study further revealed that the magnetized liposomes significantly enhanced the targeting ability, biocompatibility, and tumor inhibition effect of DHA compared to their non-magnetized counterparts.

Methods for Preparing Magnetic Hydrogels:¹⁸ (1) Blending Method: In this approach, magnetic nanoparticles are thoroughly mixed with the hydrogel precursor, followed by the initiation of the polymerization reaction. The uniform distribution of nanoparticles within the hydrogel matrix ensures consistent magnetic properties throughout the material. (2) Grafting Method: This technique utilizes functionalized magnetic nanoparticles grafted with specific functional groups. These modified nanoparticles are co-polymerized with monomers, forming covalent bonds that integrate the magnetic particles into the hydrogel network. The covalent linkage enhances the stability and durability of the magnetic hydrogel. (3) In Situ Precipitation Method: The hydrogel is first immersed in a concentrated solution containing the desired metal ions until swelling equilibrium is achieved. Subsequently, the hydrogel is treated with an alkaline solution, which induces the precipitation of magnetic nanoparticles within the hydrogel matrix. This method allows for precise control over the nanoparticle size and distribution. (4) Swelling Method: This method involves incubating the pre-formed hydrogel in a magnetic fluid. It is particularly suitable for the development of microgels, as the swelling process facilitates the incorporation of magnetic nanoparticles into the hydrogel network. The simplicity and scalability of this method make it attractive for various biomedical applications.

Rodkate et al.¹²⁶ successfully synthesized hydrogel microspheres incorporating magnetite nanoparticles (FeCl_3 , $\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$) using PNIPAM and CMC as the matrix. The synthesis was achieved through oil-in-water emulsion polymerization combined with cross-linking techniques, which were specifically designed to enable precise control over drug release (Fig. 4D). The experimental results demonstrated that the microspheres containing magnetite nanoparticles exhibited a Ms of 54.5 emu/g, which was approximately 15 times higher than that of microspheres without magnetic nanoparticles. Furthermore, it was revealed that the Ms value decreased with an increase in the content of organic components, highlighting the critical role of composition in determining the magnetic properties of the material.

3.2.3 pH-sensitive

pH-sensitive modifications, whether applied to liposomes or hydrogels, are achieved by



incorporating pH-responsive materials, thereby endowing these systems with specific pH-sensitivity.¹³⁶ The principal methodologies for fabricating pH-sensitive liposomes can be categorized as follows:¹³⁸ (1) phospholipid-based systems, (2) polymer-anchored architectures, (3) N-isopropylacrylamide-based copolymer assemblies, (4) poly(ethylacrylic acid) formulations, (5) polyphosphoric acid ester constructs, (6) poly(ethylene glycol) derivative-based systems, and (7) poly(2-ethylpropylacrylic acid) compositions.

Sonju et al.¹²⁷ successfully developed pH-sensitive liposomes (PS 5-DoxL) encapsulating peptide mimetic-doxorubicin (5-Dox) with a particle size of 170.34 ± 3.75 nm, a zeta potential of -24.57 ± 4.68 mV, and a high drug encapsulation efficiency of $88.45 \pm 1.50\%$. The drug release profile of PS 5-DoxL was evaluated under simulated physiological conditions at pH 6.5 and pH 7.4 over a 6-hour period (Fig. 4E). The study revealed that approximately 64% of 5-Dox was released under acidic conditions (pH 6.5), compared to only 48% under neutral conditions (pH 7.4). These findings indicate that the liposomes exhibit enhanced drug release efficiency in acidic environments, highlighting their potential for targeted drug delivery in pH-dependent applications.

The preparation of pH-responsive hydrogels typically involves the incorporation of pH-sensitive chemical bonds or structures, enabling the hydrogels to modulate their physical or chemical properties in response to varying pH environments. Primary preparation methods include:¹³⁷ (1) the introduction of pH-sensitive chemical bonds, (2) the use of pH-sensitive monomers, and (3) the utilization of pH-sensitive polymers. For instance, Kureha et al.¹²⁸ developed cyclodextrin-crosslinked microspheres featuring decoupled thermal and pH-responsive volume transitions. These microgels control their swelling/shrinking behavior by regulating the aggregation/depolymerization state of γ -cyclodextrin within a RC network (Fig. 4F). Moreover, the aggregation and depolymerization of the RC network, and consequently the swelling capacity of the microgel, can be similarly modulated by adjusting the pH value.

3.2.4 Photosensitive liposomes

Photosensitive liposomes are meticulously engineered by incorporating photosensitive components that meet stringent criteria, including stability under physiological conditions, superior biocompatibility, and compatibility with liposomal structures. Several strategies have been developed for integrating these photosensitive components into liposomes, as outlined below:^{139, 140} (1) direct



insertion: i.e., during hydration of the lipid membrane, the photosensitive component is mixed with the lipid, thus forming liposomes. (2) Post-Assembly: Pre-formed liposomes are exposed to the photosensitive component, which is subsequently embedded into the liposomal membrane through diffusion or post-insertion techniques. (3) The photosensitive component is anchored to the outer membrane of the liposome via covalent bonding or non-covalent interactions, ensuring its immobilization on the liposomal surface. The mechanism of light-triggered release primarily involves photoisomerization and conformational changes of the photosensitive components, as well as photothermal effects that induce thermally triggered release. Furthermore, critical factors such as light wavelength, intensity, and duration must be carefully considered, as they significantly influence the kinetics of the release process.

Enzian et al.¹⁴¹ embedded four photosensitisers (BPD, Ce6, AlPcS₂ and 5,10-DiOH) in liposome membranes. Upon light excitation at a wavelength of 420 nm, these photosensitizers generated singlet oxygen species as well as other reactive oxygen species. This oxidative activity induced chain scission and lipolysis of the liposome membranes, thereby facilitating the release of the encapsulated drug. The results demonstrated that liposomes containing 5,10-DiOH achieved more than 80% fluorescein release within just 2 minutes under 420 nm light excitation. Notably, 5,10-DiOH exhibited significantly higher efficiency compared to the other three photosensitizers.

Photosensitive hydrogels are synthesized through the integration of photosensitive precursors and photoinitiators, facilitating cross-linking or depolymerization reactions between free radicals and functional groups under specific light conditions, such as UV or blue light irradiation.^{142, 143} While these hydrogels offer the capability to modulate material microstructure through precise control of spatial cross-linking or depolymerization, thereby influencing cell behaviors including attachment, migration, and differentiation, it is noteworthy that UV irradiation may generate free radicals. These free radicals possess the potential to induce DNA damage and cellular dysfunction.¹⁴⁴

Pourbadiei et al.¹⁴⁵ successfully synthesized a copolymer by integrating azobenzene derivatives with N-isopropylacrylamide, which served as a dual-responsive component to light and heat. They further developed a Paclitaxel-loaded DAS@SCD/NIPAZO hydrogel by establishing a host-guest interaction between β -cyclodextrin and azobenzene groups. This hydrogel exhibited a 34% higher drug release rate under 365 nm light irradiation compared to the control without light at the same temperature.



3.2.5 Immunoliposome

Immunoliposomes are engineered by conjugating antibodies to the liposome surface through two primary mechanisms: covalent and non-covalent coupling.^{146, 147} Covalent coupling typically involves the formation of a stable thioether bond, achieved through reactions such as the conjugation of a thiol group with a maleimide moiety, which firmly anchors the antibody or other ligands to the liposome surface. In contrast, non-covalent coupling leverages interactions between a hydrophobic anchoring moiety and functional groups, facilitating ligand binding to the liposome surface to achieve active tissue targeting.

Rahman et al.¹⁴⁸ developed chimeric nanobodies (cNB) by isolating peripheral blood mononuclear cells from immunized alpacas to generate nanobodies targeting human epidermal growth factor receptor 2 (HER2). Subsequently, the cNB were combined with lipids at a specific ratio using ultrasonication and extrusion techniques to formulate immunoliposomes (cNB-LP) with a uniform particle size of 100 nm. These cNB-LPs demonstrated efficient drug-loading capacity and selective targeting of HER2-overexpressing cancer cells, exhibiting significant therapeutic efficacy in both *in vitro* and *in vivo* experiments.

After implementing the aforementioned optimization strategy, it is imperative to conduct a comprehensive validation of the delivery system. This validation process should encompass thorough investigation of the system's drug-loading efficiency, release kinetics, biocompatibility, and pharmacodynamic characteristics through both *in vivo* and *in vitro* experiments. These evaluations are crucial to ensure that the delivery system satisfies the practical requirements for clinical applications. Furthermore, the delivery system should be systematically refined and enhanced based on the experimental findings to optimize its performance. The modification strategies and related response materials are shown in Table 3.

Table 3. Modification strategies of LHMs and related responsive materials

Response types	Modification Strategy	Representative Responsive Materials
----------------	-----------------------	-------------------------------------



Temperature	Co-dissolve TSP in organic phase	PNIPAAm (LCST $\approx$ 32 $^{\circ}$ C)
Magnetic	Physical encapsulation / embedding of MNPs	Fe ₃ O ₄ , FeO, Fe ₂ O ₃ , MO, BaO
pH	pH-sensitive lipid or polymer insertion	DOPE-CHEMS (pH-sensitive lipid)
Light	Direct insertion of photosensitizers into	BPD, Ce6, AlPcS ₂ , 5,10-DiOH
Immuno	Covalent coupling of antibodies via maleimide-thiol chemistry	Anti-HER2 cNB

TSP: temperature-sensitive polymer; LCST: lower critical solution temperature; ECM: extracellular matrix; MNPs: magnetic nanoparticles; cNB: camelid nanobody; DOPE-CHEMS: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine/cholesteryl hemisuccinate.

After implementing the aforementioned optimization strategy, it is imperative to conduct a comprehensive validation of the delivery system. This validation process should encompass thorough investigation of the system's drug-loading efficiency, release kinetics, biocompatibility, and pharmacodynamic characteristics through both *in vivo* and *in vitro* experiments. These evaluations are crucial to ensure that the delivery system satisfies the practical requirements for clinical applications. Furthermore, the delivery system should be systematically refined and enhanced based on the experimental findings to optimize its performance.

4. Biomedical applications

4.1 Cardiovascular disease

In the treatment of cardiovascular disease, there are several difficulties, including drug efficacy and tolerance, short drug half-lives, drug combinations that increase efficacy but increase the risk of adverse events, and difficulty in measuring drugs (peptides such as angiotensin 1-7, angiotensin 1-9, or alamandine are difficult to isolate from biological samples due to the similarity in molecular structure), and studies have shown that high cholesterol is an important risk factor for cardiovascular disease.^{149, 150}

AST exhibits multiple therapeutic properties, including antioxidant, anti-proliferative, anti-apoptotic, and anti-inflammatory effects. However, its clinical application is limited by poor bioavailability, low solubility, and chemical instability.¹⁵¹ To address these challenges, Liu et al.¹²¹ developed an innovative drug delivery system utilizing AST NSC/HSA-PEG liposomes@SA/CMCS. This system not only overcomes AST's inherent limitations but also demonstrates targeted delivery to



intestinal epithelial cells through neonatal Fc receptor binding, enabling sustained release in the intestinal environment. Importantly, this formulation effectively prevents diet-induced hypercholesterolemia associated with high-fat-high-cholesterol diet. Furthermore, the liposome composite hydrogel has shown therapeutic potential in cardiovascular applications by ameliorating mitochondrial dysfunction in myocardial infarction regions and promoting angiogenesis, thereby significantly improving myocardial function.¹⁵²

4.2 Bone and cartilage diseases

The treatment of bone and cartilage diseases, particularly osteoarthritis, faces two critical challenges: maintaining long-term joint cavity lubrication and preserving the morphology of cells delivered to the joint space.^{116, 153, 154} Conventional drug delivery approaches, including oral administration and intravenous injection, are often associated with suboptimal drug bioavailability and systemic adverse effects. In comparison, localized administration strategies, particularly intra-articular injection, alleviate these shortcomings; however, they require repeated administration due to the rapid clearance of the delivery vehicle and premature release of therapeutic agents, which ultimately compromises therapeutic efficacy and increases the risk of adverse events.^{103, 155}

LHMs are the perfect solution to these problems. LHMs have a self-renewing lubrication layer, and liposomes coated on the surface of the hydrogel microspheres or inside the microspheres provide continuous lubrication during friction, thus reducing joint wear and tear, while enabling sustained release of the drug and promoting cartilage repair (Fig. 5A and B).¹²⁰ Notably, Jahanmard et al.¹⁵⁶ embedded liposomes in GelMA microspheres using electrospray technology and found that the composite structure was able to withstand certain mechanical shear forces during surgical replacement. Research has shown that GelMA/liposomes increase pro-inflammatory cytokines, stimulate osteogenesis, and promote differentiation of mesenchymal stem cells.






Fig. 5 Therapeutic Potential of LHMs in Bone and Cartilage Disorders, Promoting wound healing in a full-thickness skin injury model of diabetic patients. (A) 3D reconstruction images, coronal, sagittal, and transverse images of mouse knee microCT. (B) Representative X-ray films of the mice knee joints in anterior-posterior and lateral. ¹²⁰, Copyright 2024. Reproduced with permission from Wiley. (C) Representative pictures of wound healing in different treatment groups on days 0, 3, 7, 10 and 14. (D) The schematic diagram of the wound healing process. ⁸³, Copyright 2024. Reproduced with permission from Spring Nature.

4.3 Wound repair

LHMs are gaining prominence in the field of wound repair due to their versatile therapeutic potential.^{73, 157} In the management of chronic wounds, such as diabetic foot ulcers¹⁵⁸ and pressure ulcers¹⁵⁹, LHMs have demonstrated efficacy in promoting accelerated wound healing while concurrently mitigating infection rates and reducing the likelihood of recurrence. In burn wound care, LHMs facilitate the establishment of a moist wound environment endowed with antimicrobial properties, thereby enhancing the epithelialization process. Furthermore, in post-surgical wound care, LHMs significantly diminish the risk of postoperative infections, underscoring their clinical utility.

Diabetic wounds tend to develop into complex and severe chronic wounds, which are difficult to treat, slow to heal and have multiple obstacles to the healing process, such as bacterial infections,

ulcers, necrosis and other complications; liposomes combined with hydrogels and loaded with drugs can inhibit the inflammatory response, promote angiogenesis and tissue remodelling, thus speeding up the wound healing process.^{92, 160, 161} Guo et al.⁸³ developed nanoliposomal composite hydrogel microspheres (PPD-Lipo@HMs) incorporating the natural active compound 20(S)-protopanaxadiol (PPD) through microfluidic technology. The PPD-Lipo@HMs demonstrated significant biological activity by stimulating vascular endothelial growth factor expression, thereby promoting endothelial cell migration, neovascularization, and tissue regeneration. Notably, the aggregation of PPD-Lipo@HMs forms microsphere folds that effectively cover damaged tissues, facilitating fibroblast and endothelial cell attachment, spreading, and proliferation. This unique structural feature contributes to the accelerated healing of diabetic wounds (Fig. 5C and D).

4.4 Sensorineural hearing loss

Achieving safe and efficient drug delivery across the blood-labyrinth barrier to the inner ear remains a significant challenge in the prevention and treatment of sensorineural hearing loss. Hydrogel-based composite drug delivery systems have emerged as a promising solution, demonstrating dual capabilities of facilitating targeted inner ear delivery and overcoming the blood-labyrinth barrier restriction while maintaining sustained drug release.¹⁶² Notably, injectable hydrogel microspheres (GM@PDA@Lipo-Ebselen) with bioadhesive properties have shown therapeutic efficacy through their adherence to the round window membrane in murine models. These microspheres effectively reduced reactive oxygen species production, mitigated mitochondrial dysfunction, and minimized the loss of hair cells and synaptic connections. Consequently, they demonstrated significant improvement in noise-induced hearing loss in murine subjects.¹¹⁷

4.5 Anti-tumour therapy

The primary challenges in drug-based tumor treatment include the high heterogeneity of tumor cells, immune evasion, the development of drug resistance, as well as significant side effects and high treatment costs.¹⁶³ LHMs partially mitigate these issues. They can be utilized for localized tumor therapy by encapsulating antitumor drugs, enabling precise and sustained drug release, remodeling the tumor microenvironment, reducing systemic toxicity, and simultaneously increasing targeted drug concentrations to enhance therapeutic efficacy.^{164, 165}



The CRISPR/Cas9 nuclease system¹⁶⁶ is widely regarded as one of the most promising genome editing technologies for cancer therapy. Previous studies have often employed viruses for delivery; however, clinical translation remains a significant challenge when using viral vectors. To address this, Chen et al.¹⁶⁷ developed a novel composite delivery system comprising a polyethyleneimine hydrogel core and a cationic liposome shell. In this system, the polyethyleneimine hydrogel encapsulates the Cas9 protein, while the cationic liposomes deliver the genetic material. Leveraging the host-guest interaction between cyclodextrin and adamantane, a mechanically soft structure was constructed, which effectively preserved protein activity. Notably, this composite delivery system demonstrated significant inhibition of tumor growth and a substantial reduction in tumor volume compared to control groups.

4.6 Vaccine delivery

In clinical applications, vaccines face many challenges. Most synthetic peptides are poorly immunogenic and therefore require adjuvants to enhance their ability to stimulate an immune response; in addition, proteins are extremely sensitive to organic solvents, which may impair their natural antigenic properties, resulting in altered immunogenicity and adverse immune responses.^{98, 168} To address these limitations, we have implemented an innovative approach by utilizing the LHMs drug delivery system for effective vaccine encapsulation and delivery.

Machluf M et al.⁷⁸ developed an innovative vaccine delivery system by encapsulating recombinant hepatitis B surface antigen (HBsAg)-loaded liposomes within calcium alginate-based microspheres, which were subsequently surface-modified with polylysine. Their experimental results demonstrated that this composite microsphere system effectively achieved sustained antigen release and maintained an antigen depot effect. Notably, this novel delivery platform significantly reduced the required vaccine dosage while eliminating the necessity for booster immunizations, thereby representing a promising approach for vaccine development.

For different diseases, either the modification of liposomes or the modification of hydrogels will confer some specific functions to the LHMs drug delivery system. This not only improves the efficiency of drug administration, but also avoids to some extent the shortcomings when used alone (Table 4).



Table 4. Modification strategies of LHMs and related responsive materials

Modification	Specific functions	Application
GelMA	Controlled-release	Osteoarthritis, bone injury
Sodium Alginate	pH-sensitive	Myocardial injury
CMCS, HSA	pH-sensitive, Enhance targeting	Hypercholesterolemia
BSPMA	Structural support and microenvironment regulation	Diabetic wound
internalizing RGD	Enhance targeting	Tumor
alginate-poly(L-lysine)	Controlled-release	Delivery of HBsAg

5. Current challenges

LHMs as an advanced drug delivery system that integrates nanotechnology with hydrogel technology, demonstrate significant potential in the field of drug delivery. Nevertheless, several challenges persist in their practical applications.

5.1 High technical barriers

The preparation of LHMs is a complex and multifaceted process. While liposome preparation and modification technologies are well-established, the fabrication of nanoscale hydrogel microspheres continues to face significant technical hurdles. For instance, microfluidic devices, which are inherently limited in scalability for large-scale batch production, often exhibit inconsistencies in performance, resulting in significant batch-to-batch variability.^{72, 117, 169} The second critical aspect concerns the interfacial compatibility issue between liposomes and hydrogels. Beyond conventional integration approaches that involve either the encapsulation of liposomes within the hydrogel matrix or their surface adsorption onto hydrogel microspheres, establishing robust chemical bonding between drug-loaded liposomes and hydrogel microspheres while simultaneously endowing the system with precise environmental responsiveness remains a significant scientific challenge.^{3, 17}

5.2 High production costs

The fabrication of liposomes and their hydrogel-based composites necessitates the utilization of diverse essential raw materials. Liposome preparation predominantly employs phospholipids, cholesterol, and DSPE-PEG2000²⁹, whereas hydrogel matrices are typically constructed using biomaterials including gelatin¹⁰³, GelMA¹⁵⁶ and chitosan¹²². The synthesis process further requires the use of organic solvents (e.g., chloroform and methanol)¹⁰⁴, and crosslinking agents (e.g., CaCl₂)¹⁷⁰. To



confer intelligent responsiveness to the delivery system, specific modifications to either the liposomes or the composite microspheres are necessary^{20, 41}, which inevitably increases production costs. Therefore, the development of novel raw materials is crucial to reduce costs and streamline the preparation process.

5.3 Stability and safety issues

Liposomes, owing to their unique structural composition, exhibit high susceptibility to degradation by gastric acid, bile salts, and pancreatic lipase within the gastrointestinal tract following oral administration as drug delivery vehicles. This vulnerability often results in structural disintegration of the liposomes and subsequent payload leakage.¹⁷¹ Hydrogels, in contrast, demonstrate digestive behaviors that are predominantly governed by their compositional properties and the activity of specific digestive enzymes (e.g., amylase, trypsin, pepsin, and pancreatic lipase). Furthermore, their performance in the gastrointestinal tract is influenced by variations in environmental parameters, including pH and ionic strength.¹⁷² Drug-loading LHMs have significantly improved anti-digestive ability. However, as more materials are compounded, their safety becomes increasingly complex. Moreover, the storage conditions for LHMs may not be altered due to the inherent nature of certain drugs. Consequently, it is particularly challenging to modify the storage conditions of the drug by altering the properties of the carrier while ensuring that the properties of the loaded drug remain unchanged.

5.4 Targeting and delivery efficiency

Although LHMs drug delivery systems demonstrate potential for targeted drug delivery, their delivery efficiency and targeting accuracy in complex *in vivo* environments require further optimization in practical applications. Specifically, the distribution and residence time of these microspheres within the body must be fine-tuned to ensure precise drug delivery to lesion sites.^{121, 122} For example, for the treatment of disc degeneration, there is a need to ensure that LHMs are able to fully reach and act in the nutrient-restricted microenvironment of the disc. To cope with the complexity of the *in vivo* environment, LHMs can be designed for use in specific microenvironments. However, how to do this in a way that ensures accuracy at the lesion site is still a challenge.¹⁷³

5.5 Intelligent response



LHMs have the following shortcomings in intelligent response: The response sensitivity is insufficient for accurate perception of environmental changes; the preparation process is complex, limiting large-scale production; some materials are cytotoxic.¹⁷⁴⁻¹⁷⁶ The following solutions can be adopted: optimize materials (e.g., develop new temperature-sensitive polymers) to improve response efficiency; enhance stability through interfacial chemical bonding; simplify the process by employing modular design; and ensure safety by selecting non-toxic materials and conducting long-term toxicity studies.

To address these challenges, it is essential to optimize the composition and structure of liposome to minimize the risks of rupture and fusion, while exploring novel stabilizers or cross-linking agents to enhance the stability of both liposomes and hydrogels. Development of novel targeting ligands or modification methods to improve the targeting of LHMs, in-depth study of the distribution and retention mechanisms of microspheres *in vivo*, and optimisation of delivery strategies, reducing the body's immune response and toxicity, conducting long-term toxicity studies and safety assessments, and ensuring the safety of the entire delivery system. Optimize preparation processes and reduce costs, research new preparation processes and equipment, improve production efficiency and product quality, synthetic materials to replace traditional materials, reduce production costs and expand applications. Introducing environmentally responsive hydrogels or modified liposomes into drug delivery systems, designing drug delivery systems with intelligent responsiveness, and automatically adjusting the release rate, and dose of drugs according to changes in internal and external environments, thereby improving the accuracy of treatment.

6. Conclusions and outlook

Liposomes, whether loaded with water-soluble or fat-soluble drugs, can be modified to significantly extend their circulation time in the bloodstream, thereby enhancing drug bioavailability and mitigating toxic effects. However, liposomes exhibit certain limitations. For instance, they are susceptible to degradation by the digestive system when administered orally. Furthermore, when directly injected into bone joints, liposomes fail to simultaneously achieve the dual objectives of slowing bone wear and controlled drug release. Hydrogels exhibit superior biocompatibility compared to liposomes. By immobilizing drug-loaded liposomes within the three-dimensional network of hydrogels through mechanisms such as physical



adsorption, embedding, non-covalent interactions, or chemical cross-linking, the drug loading capacity and bioavailability are significantly enhanced. Moreover, the composite drug delivery system enables precise control and sustained release of therapeutic agents while effectively resisting digestive degradation, thereby significantly reducing administration frequency.

LHMs represent a groundbreaking class of drug delivery systems with substantial research potential and promising applications. Advances in materials science and nanotechnology, coupled with ongoing technological innovation and practical experimentation, are expected to drive the evolution of these systems toward greater efficiency, safety, and intelligence. Consequently, LHMs are anticipated to gain broader adoption and promotion in the fields of drug delivery and tissue engineering.

7. Author contributions

The manuscript was written through contributions of all. All authors have given approval to the final version of the manuscript.

8. Declarations

On behalf of all authors, the corresponding author states that there is no conflict of interest.

9. Data availability

The data and information presented in this review are based on previously published studies, which are cited throughout the article.

10. Conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

11. Acknowledgements

This work was supported by the National Natural Science Foundation of China (82272237, 82270595, 82300648, and 82430083), Key Research and Development Program of Jiangsu Province (BE2023810), Jiangsu Provincial Medical Innovation Center (CXZX202217), and General Program of Medical Research from the Jiangsu Commission of Health (MQ2024031).



References:

1. Beach MA, Nayanathara U, Gao Y, *et al.*, Polymeric Nanoparticles for Drug Delivery, *Chemical reviews*. 2024, **124**(9),5505-5616, doi:10.1021/acs.chemrev.3c00705.
2. Zhang Y, Sun C, Wang C, *et al.*, Lipids and Lipid Derivatives for RNA Delivery, *Chemical reviews*. 2021, **121**(20),12181-12277, doi:10.1021/acs.chemrev.1c00244.
3. Sanati M, Amin Yavari S, Liposome-integrated hydrogel hybrids: Promising platforms for cancer therapy and tissue regeneration, *Journal of controlled release : official journal of the Controlled Release Society*. 2024, **368**,703-727, doi:10.1016/j.jconrel.2024.03.008.
4. Khare P, Edgecomb SX, Hamadani CM, *et al.*, Lipid nanoparticle-mediated drug delivery to the brain, *Advanced drug delivery reviews*. 2023, **197**,114861, doi:10.1016/j.addr.2023.114861.
5. Mikhail AS, Morhard R, Mauda-Havakuk M, *et al.*, Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer, *Advanced drug delivery reviews*. 2023, **202**,115083, doi:10.1016/j.addr.2023.115083.
6. Ahadian S, Finbloom JA, Mofidfar M, *et al.*, Micro and nanoscale technologies in oral drug delivery, *Advanced drug delivery reviews*. 2020, **157**,37-62, doi:10.1016/j.addr.2020.07.012.
7. Bangham AD, Standish MM, Watkins JC, Diffusion of univalent ions across the lamellae of swollen phospholipids, *Journal of molecular biology*. 1965, **13**(1),238-252, doi:10.1016/s0022-2836(65)80093-6.
8. Castañeda-Reyes ED, Perea-Flores MJ, Davila-Ortiz G, *et al.*, Development, Characterization and Use of Liposomes as Amphipathic Transporters of Bioactive Compounds for Melanoma Treatment and Reduction of Skin Inflammation: A Review, *International journal of nanomedicine*. 2020, **15**,7627-7650, doi:10.2147/ijn.S263516.
9. Eygeris Y, Gupta M, Kim J, *et al.*, Chemistry of Lipid Nanoparticles for RNA Delivery, *Accounts of chemical research*. 2022, **55**(1),2-12, doi:10.1021/acs.accounts.1c00544.
10. Yingchoncharoen P, Kalinowski DS, Richardson DR, Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come, *Pharmacological reviews*. 2016, **68**(3),701-787, doi:10.1124/pr.115.012070.
11. Li Z, Wu C, Liu Z, *et al.*, A polypropylene mesh coated with interpenetrating double network hydrogel for local drug delivery in temporary closure of open abdomen, *RSC advances*. 2020, **10**(3),1331-1340, doi:10.1039/c9ra10455k.
12. Huang J, Jiang Y, Ren Y, *et al.*, Biomaterials and biosensors in intestinal organoid culture, a progress review, *Journal of biomedical materials research Part A*. 2020, **108**(7),1501-1508, doi:10.1002/jbm.a.36921.
13. Huang J, Li Z, Hu Q, *et al.*, Bioinspired Anti-digestive Hydrogels Selected by a Simulated Gut Microfluidic Chip for Closing Gastrointestinal Fistula, *iScience*. 2018, **8**,40-48, doi:10.1016/j.isci.2018.09.011.
14. Huang J, Ren J, Chen G, *et al.*, Tunable sequential drug delivery system based on chitosan/hyaluronic acid hydrogels and PLGA microspheres for management of non-healing infected wounds, *Materials science & engineering C, Materials for biological applications*. 2018, **89**,213-222, doi:10.1016/j.msec.2018.04.009.
15. Qu G, Huang J, Gu G, *et al.*, Smart implants: 4D-printed shape-morphing scaffolds for medical implantation, *International journal of bioprinting*. 2023, **9**(5),764, doi:10.18063/ijb.764.



- 1001 16. Liu Y, Huang Q, Wang J, *et al.*, Microfluidic generation of egg-derived protein microcarriers
1002 for 3D cell culture and drug delivery, *Science bulletin*. 2017, **62**(18),1283-1290,
1003 **doi:10.1016/j.scib.2017.09.006**.
- 1004 17. Binaymotlagh R, Hajareh Haghighi F, Chronopoulou L, *et al.*, Liposome-Hydrogel Composites
1005 for Controlled Drug Delivery Applications, *Gels (Basel, Switzerland)*. 2024, **10**(4),284,
1006 **doi:10.3390/gels10040284**.
- 1007 18. Veloso SRS, Andrade RGD, Castanheira EMS, Review on the advancements of magnetic gels:
1008 towards multifunctional magnetic liposome-hydrogel composites for biomedical applications,
1009 *Advances in colloid and interface science*. 2021, **288**,102351, **doi:10.1016/j.cis.2020.102351**.
- 1010 19. Large DE, Abdelmessih RG, Fink EA, *et al.*, Liposome composition in drug delivery design,
1011 synthesis, characterization, and clinical application, *Advanced drug delivery reviews*. 2021,
1012 **176**,113851, **doi:10.1016/j.addr.2021.113851**.
- 1013 20. Fan Y, Wang Q, Lin G, *et al.*, Combination of using prodrug-modified cationic liposome
1014 nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and
1015 docetaxel for CD44-overexpressed triple negative breast cancer therapy, *Acta biomaterialia*.
1016 2017, **62**,257-272, **doi:10.1016/j.actbio.2017.08.034**.
- 1017 21. Stephen S, Gorain B, Choudhury H, *et al.*, Exploring the role of mesoporous silica nanoparticle
1018 in the development of novel drug delivery systems, *Drug delivery and translational research*.
1019 2022, **12**(1),105-123, **doi:10.1007/s13346-021-00935-4**.
- 1020 22. He Y, Sun M, Wang J, *et al.*, Chondroitin sulfate microspheres anchored with drug-loaded
1021 liposomes play a dual antioxidant role in the treatment of osteoarthritis, *Acta biomaterialia*.
1022 2022, **151**,512-527, **doi:10.1016/j.actbio.2022.07.052**.
- 1023 23. Cullis PR, Felgner PL, The 60-year evolution of lipid nanoparticles for nucleic acid delivery,
1024 *Nature reviews Drug discovery*. 2024, **23**(9),709-722, **doi:10.1038/s41573-024-00977-6**.
- 1025 24. He S, Fu Y, Tan Z, *et al.*, Optimization of Ultra-Small Nanoparticles for Enhanced Drug
1026 Delivery, *BIO Integration*. 2023, **4**(2), **doi:10.15212/bioi-2022-0015**.
- 1027 25. Chong ETJ, Ng JW, Lee P-C, Classification and Medical Applications of Biomaterials—A Mini
1028 Review, *BIO Integration*. 2023, **4**(2), **doi:10.15212/bioi-2022-0009**.
- 1029 26. Alavi M, Karimi N, Safaei M, Application of Various Types of Liposomes in Drug Delivery
1030 Systems, *Advanced pharmaceutical bulletin*. 2017, **7**(1),3-9, **doi:10.15171/apb.2017.002**.
- 1031 27. Ajeeshkumar KK, Aneesh PA, Raju N, *et al.*, Advancements in liposome technology:
1032 Preparation techniques and applications in food, functional foods, and bioactive delivery: A
1033 review, *Comprehensive reviews in food science and food safety*. 2021, **20**(2),1280-1306,
1034 **doi:10.1111/1541-4337.12725**.
- 1035 28. Kansız S, Elçin YM, Advanced liposome and polymersome-based drug delivery systems:
1036 Considerations for physicochemical properties, targeting strategies and stimuli-sensitive
1037 approaches, *Advances in colloid and interface science*. 2023, **317**,102930,
1038 **doi:10.1016/j.cis.2023.102930**.
- 1039 29. Shah S, Dhawan V, Holm R, *et al.*, Liposomes: Advancements and innovation in the
1040 manufacturing process, *Advanced drug delivery reviews*. 2020, **154-155**,102-122,
1041 **doi:10.1016/j.addr.2020.07.002**.
- 1042 30. Cheng CY, Lai YF, Hsieh YL, *et al.*, Divergent effects of cholesterol on the structure and
1043 fluidity of liposome and catanionic vesicle membranes, *FEBS letters*. 2022, **596**(14),1827-1838,
1044 **doi:10.1002/1873-3468.14375**.



- 1045 31. Nsairat H, Ibrahim AA, Jaber AM, *et al.*, Liposome bilayer stability: emphasis on cholesterol
1046 and its alternatives, *Journal of liposome research*. 2024, **34**(1),178-202,
1047 **doi:10.1080/08982104.2023.2226216**.
- 1048 32. Zhu R, Yin Z, Liu N, *et al.*, Polymyxin B-Modified Fosfomycin Liposomes Target Gram-
1049 Negative Bacteria and Exert Synergistic Antibacterial Effect, *ACS omega*. 2023, **8**(48),45914-
1050 45923, **doi:10.1021/acsomega.3c06719**.
- 1051 33. Jang YJ, Kang SJ, Park HS, *et al.*, Drug delivery strategies with lipid-based nanoparticles for
1052 Alzheimer's disease treatment, *Journal of nanobiotechnology*. 2025, **23**(1),99,
1053 **doi:10.1186/s12951-025-03109-3**.
- 1054 34. Zhang H, Thin-Film Hydration Followed by Extrusion Method for Liposome Preparation,
1055 *Methods in molecular biology (Clifton, NJ)*. 2023, **2622**,57-63, **doi:10.1007/978-1-0716-2954-3_4**.
1056
- 1057 35. Thabet Y, Elsabahy M, Eissa NG, Methods for preparation of niosomes: A focus on thin-film
1058 hydration method, *Methods (San Diego, Calif)*. 2022, **199**,9-15,
1059 **doi:10.1016/j.ymeth.2021.05.004**.
- 1060 36. Mirveis Z, Kouchak M, Mahdavinia M, *et al.*, Novel and efficient method for loading aptamer-
1061 conjugated liposomes with arsenic trioxide for targeting cancer cells, *Journal of liposome*
1062 *research*. 2022, **32**(3),276-283, **doi:10.1080/08982104.2021.2005624**.
- 1063 37. Zhang M, Xiang C, Niu R, *et al.*, Liposomes as versatile agents for the management of traumatic
1064 and nontraumatic central nervous system disorders: drug stability, targeting efficiency, and
1065 safety, *Neural regeneration research*. 2025, **20**(7),1883-1899, **doi:10.4103/nrr.Nrr-d-24-00048**.
1066
- 1067 38. Pham HL, Shaw PN, Davies NM, Preparation of immuno-stimulating complexes (ISCOMs) by
1068 ether injection, *International journal of pharmaceutics*. 2006, **310**(1-2),196-202,
1069 **doi:10.1016/j.ijpharm.2005.11.011**.
- 1070 39. Du G, Sun X, Ethanol Injection Method for Liposome Preparation, *Methods in molecular*
1071 *biology (Clifton, NJ)*. 2023, **2622**,65-70, **doi:10.1007/978-1-0716-2954-3_5**.
- 1072 40. Duong TT, Isomäki A, Paaver U, *et al.*, Nanoformulation and Evaluation of Oral Berberine-
1073 Loaded Liposomes, *Molecules (Basel, Switzerland)*. 2021, **26**(9),2591,
1074 **doi:10.3390/molecules26092591**.
- 1075 41. Li W, Chen D, Zhu Y, *et al.*, Alleviating Pyroptosis of Intestinal Epithelial Cells to Restore
1076 Mucosal Integrity in Ulcerative Colitis by Targeting Delivery of 4-Octyl-Itaconate, *ACS nano*.
1077 2024, **18**(26),16658-16673, **doi:10.1021/acsnano.4c01520**.
- 1078 42. Cyr Y, Bozal FK, Barcia Durán JG, *et al.*, The IRG1-itaconate axis protects from cholesterol-
1079 induced inflammation and atherosclerosis, *Proceedings of the National Academy of Sciences of*
1080 *the United States of America*. 2024, **121**(15),e2400675121, **doi:10.1073/pnas.2400675121**.
- 1081 43. Zhang Q, Qin Y, Duan G, *et al.*, A Microstructural Study of the O/W Primary Emulsion on the
1082 Formation of Oil-in-Water-in-Oil Multiple Emulsion, *Current drug delivery*. 2021, **18**(7),994-
1083 1002, **doi:10.2174/1567201818666210101114517**.
- 1084 44. Ogata Y, Kuroiwa T, Ichikawa S, Facilitated encapsulation of a nonionic contrast agent for X-
1085 ray computed tomography into lipid vesicles by the multiple emulsification-solvent evaporation
1086 method, *Colloids and surfaces B, Biointerfaces*. 2023, **227**,113360,
1087 **doi:10.1016/j.colsurfb.2023.113360**.



- 1088 45. Malik DJ, Sokolov IJ, Vinner GK, *et al.*, Formulation, stabilisation and encapsulation of
1089 bacteriophage for phage therapy, *Advances in colloid and interface science*. 2017, **249**,100-133,
1090 **doi:10.1016/j.cis.2017.05.014**.
- 1091 46. Salehi B, Selamoglu Z, K SM, *et al.*, Liposomal Cytarabine as Cancer Therapy: From Chemistry
1092 to Medicine, *Biomolecules*. 2019, **9**(12),773, **doi:10.3390/biom9120773**.
- 1093 47. Cortesi R, Esposito E, Gambarin S, *et al.*, Preparation of liposomes by reverse-phase
1094 evaporation using alternative organic solvents, *Journal of microencapsulation*. 1999, **16**(2),251-
1095 256, **doi:10.1080/026520499289220**.
- 1096 48. Liu C, Liu YY, Chang Q, *et al.*, Pressure-Controlled Encapsulation of Graphene Quantum Dots
1097 into Liposomes by the Reverse-Phase Evaporation Method, *Langmuir : the ACS journal of*
1098 *surfaces and colloids*. 2021, **37**(48),14096-14104, **doi:10.1021/acs.langmuir.1c02338**.
- 1099 49. Liu XL, Dong X, Yang SC, *et al.*, Biomimetic Liposomal Nanoplatinum for Targeted Cancer
1100 Chemophototherapy, *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*. 2021,
1101 **8**(8),2003679, **doi:10.1002/advs.202003679**.
- 1102 50. Szoka F, Olson F, Heath T, *et al.*, Preparation of unilamellar liposomes of intermediate size
1103 (0.1-0.2 μ m) by a combination of reverse phase evaporation and extrusion through
1104 polycarbonate membranes, *Biochimica et biophysica acta*. 1980, **601**(3),559-571,
1105 **doi:10.1016/0005-2736(80)90558-1**.
- 1106 51. Vemuri S, Rhodes CT, Development and characterization of a liposome preparation by a pH-
1107 gradient method, *The Journal of pharmacy and pharmacology*. 1994, **46**(10),778-783,
1108 **doi:10.1111/j.2042-7158.1994.tb03729.x**.
- 1109 52. Wang S, Liu C, Wang C, *et al.*, Arsenic trioxide encapsulated liposomes prepared via copper
1110 acetate gradient loading method and its antitumor efficiency, *Asian journal of pharmaceutical*
1111 *sciences*. 2020, **15**(3),365-373, **doi:10.1016/j.ajps.2018.12.002**.
- 1112 53. Ahmed ETM, Hassan M, Shamma RN, *et al.*, Controlling the Evolution of Selective
1113 Vancomycin Resistance through Successful Ophthalmic Eye-Drop Preparation of Vancomycin-
1114 Loaded Nanoliposomes Using the Active-Loading Method, *Pharmaceutics*. 2023, **15**(6),1636,
1115 **doi:10.3390/pharmaceutics15061636**.
- 1116 54. Vemuri S, Rhodes CT, Preparation and characterization of liposomes as therapeutic delivery
1117 systems: a review, *Pharmaceutica acta Helveticae*. 1995, **70**(2),95-111, **doi:10.1016/0031-**
1118 **6865(95)00010-7**.
- 1119 55. Hwang SH, Maitani Y, Qi XR, *et al.*, Remote loading of diclofenac, insulin and fluorescein
1120 isothiocyanate labeled insulin into liposomes by pH and acetate gradient methods, *International*
1121 *journal of pharmaceutics*. 1999, **179**(1),85-95, **doi:10.1016/s0378-5173(98)00392-5**.
- 1122 56. Ramanjulu JM, Pesiridis GS, Yang J, *et al.*, Design of amidobenzimidazole STING receptor
1123 agonists with systemic activity, *Nature*. 2018, **564**(7736),439-443, **doi:10.1038/s41586-018-**
1124 **0705-y**.
- 1125 57. Zhang J, Cui X, Huang Y, *et al.*, Anticancer Effect of STING Agonist-Encapsulated Liposomes
1126 on Breast Cancer, *Molecules (Basel, Switzerland)*. 2023, **28**(9),3740,
1127 **doi:10.3390/molecules28093740**.
- 1128 58. Wang T, Wang N, Wang T, *et al.*, Preparation of submicron liposomes exhibiting efficient
1129 entrapment of drugs by freeze-drying water-in-oil emulsions, *Chemistry and physics of lipids*.
1130 2011, **164**(2),151-157, **doi:10.1016/j.chemphyslip.2010.12.005**.



- 1131 59. Has C, Sunthar P, A comprehensive review on recent preparation techniques of liposomes, *Journal of liposome research*. 2020, **30**(4),336-365, doi:10.1080/08982104.2019.1668010. View Article Online
DOI: 10.1039/D5TB01369K
- 1132
- 1133 60. Izutsu KI, Applications of Freezing and Freeze-Drying in Pharmaceutical Formulations, *Advances in experimental medicine and biology*. 2018, **1081**,371-383, doi:10.1007/978-981-13-1244-1_20.
- 1134
- 1135
- 1136 61. Tanaka H, Hagiwara S, Shirane D, *et al.*, Ready-to-Use-Type Lyophilized Lipid Nanoparticle Formulation for the Postencapsulation of Messenger RNA, *ACS nano*. 2023, **17**(3),2588-2601, doi:10.1021/acsnano.2c10501.
- 1137
- 1138
- 1139 62. Sahin U, Karikó K, Türeci Ö, mRNA-based therapeutics--developing a new class of drugs, *Nature reviews Drug discovery*. 2014, **13**(10),759-780, doi:10.1038/nrd4278.
- 1140
- 1141 63. Penoy N, Grignard B, Evrard B, *et al.*, A supercritical fluid technology for liposome production and comparison with the film hydration method, *International journal of pharmaceutics*. 2021, **592**,120093, doi:10.1016/j.ijpharm.2020.120093.
- 1142
- 1143
- 1144 64. Chakravarty P, Famili A, Nagapudi K, *et al.*, Using Supercritical Fluid Technology as a Green Alternative During the Preparation of Drug Delivery Systems, *Pharmaceutics*. 2019, **11**(12),629, doi:10.3390/pharmaceutics11120629.
- 1145
- 1146
- 1147 65. Falconer JR, Svirskis D, Adil AA, *et al.*, Supercritical Fluid Technologies to Fabricate Proliposomes, *Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques*. 2015, **18**(5),747-764, doi:10.18433/j3qp58.
- 1148
- 1149
- 1150
- 1151 66. Rothenberg ML, Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond, *The oncologist*. 2001, **6**(1),66-80, doi:10.1634/theoncologist.6-1-66.
- 1152
- 1153 67. Mohammadi M, Karimi M, Raofie F, Preparation irinotecan hydrochloride loaded PEGylated liposomes using novel method supercritical fluid and condition optimized by Box-Behnken design, *Discover nano*. 2024, **19**(1),141, doi:10.1186/s11671-024-04071-z.
- 1154
- 1155
- 1156 68. Karn PR, Kim HD, Kang H, *et al.*, Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion, *International journal of nanomedicine*. 2014, **9**,3791-3800, doi:10.2147/ijn.S65601.
- 1157
- 1158
- 1159
- 1160 69. Maeki M, Uno S, Niwa A, *et al.*, Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery, *Journal of controlled release : official journal of the Controlled Release Society*. 2022, **344**,80-96, doi:10.1016/j.jconrel.2022.02.017.
- 1161
- 1162
- 1163 70. Wang X, Liu J, Wang P, *et al.*, Synthesis of Biomaterials Utilizing Microfluidic Technology, *Genes*. 2018, **9**(6),283, doi:10.3390/genes9060283.
- 1164
- 1165 71. Gu Y, Jin L, Wang L, *et al.*, Preparation of Baicalin Liposomes Using Microfluidic Technology and Evaluation of Their Antitumor Activity by a Zebrafish Model, *ACS omega*. 2024, **9**(40),41289-41300, doi:10.1021/acsomega.4c03356.
- 1166
- 1167
- 1168 72. Cao H, Duan L, Zhang Y, *et al.*, Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity, *Signal transduction and targeted therapy*. 2021, **6**(1),426, doi:10.1038/s41392-021-00830-x.
- 1169
- 1170
- 1171 73. Ji S, Li Y, Xiang L, *et al.*, Cocktail Cell-Reprogrammed Hydrogel Microspheres Achieving Scarless Hair Follicle Regeneration, *Advanced science (Weinheim, Baden-Wurtemberg, Germany)*. 2024, **11**(12),e2306305, doi:10.1002/advs.202306305.
- 1172
- 1173



- 1174 74. Bobone S, Miele E, Cerroni B, *et al.*, Liposome-Templated Hydrogel Nanoparticles as Vehicles
1175 for Enzyme-Based Therapies, *Langmuir : the ACS journal of surfaces and colloids*. 2015,
1176 **31**(27),7572-7580, **doi:10.1021/acs.langmuir.5b01442**.
- 1177 75. Fan R, Wu J, Duan S, *et al.*, Droplet-based microfluidics for drug delivery applications,
1178 *International journal of pharmaceutics*. 2024, **663**,124551,
1179 **doi:10.1016/j.ijpharm.2024.124551**.
- 1180 76. Chen L, Yang J, Cai Z, *et al.*, Mitochondrial-Oriented Injectable Hydrogel Microspheres
1181 Maintain Homeostasis of Chondrocyte Metabolism to Promote Subcellular Therapy in
1182 Osteoarthritis, *Research (Washington, DC)*. 2024, **7**,0306, **doi:10.34133/research.0306**.
- 1183 77. Schulze J, Hendrikx S, Schulz-Siegmund M, *et al.*, Microparticulate poly(vinyl alcohol)
1184 hydrogel formulations for embedding and controlled release of polyethylenimine (PEI)-based
1185 nanoparticles, *Acta biomaterialia*. 2016, **45**,210-222, **doi:10.1016/j.actbio.2016.08.056**.
- 1186 78. Machluf M, Apte RN, Regev O, *et al.*, Enhancing the immunogenicity of liposomal hepatitis B
1187 surface antigen (HBsAg) by controlling its delivery from polymeric microspheres, *Journal of*
1188 *pharmaceutical sciences*. 2000, **89**(12),1550-1557, **doi:10.1002/1520-**
1189 **6017(200012)89:12<1550::aid-jps5>3.0.co;2-z**.
- 1190 79. Kumari S, Goyal A, Sönmez Gürer E, *et al.*, Bioactive Loaded Novel Nano-Formulations for
1191 Targeted Drug Delivery and Their Therapeutic Potential, *Pharmaceutics*. 2022, **14**(5),1091,
1192 **doi:10.3390/pharmaceutics14051091**.
- 1193 80. Sharma P, Pandita A, Murthy RS, Concepts and Strategies for the Site Specific Delivery of
1194 Nanocarrier Based Delivery Systems for Treating Hepatocellular Carcinoma, *Current drug*
1195 *delivery*. 2013,57-77,
- 1196 81. Zhang C, Zeng Y, Xu N, *et al.*, [Cell-loaded hydrogel microspheres based on droplet
1197 microfluidics: a review], *Sheng wu gong cheng xue bao = Chinese journal of biotechnology*.
1198 2023, **39**(1),74-85, **doi:10.13345/j.cjb.220341**.
- 1199 82. Zheng F, Tian R, Lu H, *et al.*, Droplet Microfluidics Powered Hydrogel Microparticles for Stem
1200 Cell-Mediated Biomedical Applications, *Small (Weinheim an der Bergstrasse, Germany)*. 2024,
1201 **20**(42),e2401400, **doi:10.1002/sml.202401400**.
- 1202 83. Guo P, Lei P, Luo L, *et al.*, Microfluidic-engineered Chinese herbal nanocomposite hydrogel
1203 microspheres for diabetic wound tissue regeneration, *Journal of nanobiotechnology*. 2024,
1204 **22**(1),724, **doi:10.1186/s12951-024-02998-0**.
- 1205 84. Miao K, Zhou Y, He X, *et al.*, Microenvironment-responsive bilayer hydrogel microspheres
1206 with gelatin-shell for osteoarthritis treatment, *International journal of biological*
1207 *macromolecules*. 2024, **261**(Pt 2),129862, **doi:10.1016/j.ijbiomac.2024.129862**.
- 1208 85. Tanhaei A, Mohammadi M, Hamishehkar H, *et al.*, Electrospraying as a novel method of
1209 particle engineering for drug delivery vehicles, *Journal of controlled release : official journal*
1210 *of the Controlled Release Society*. 2021, **330**,851-865, **doi:10.1016/j.jconrel.2020.10.059**.
- 1211 86. Deng Y, Li J, Tao R, *et al.*, Molecular Engineering of Electrosprayed Hydrogel Microspheres
1212 to Achieve Synergistic Anti-Tumor Chemo-Immunotherapy with ACEA Cargo, *Advanced*
1213 *science (Weinheim, Baden-Wurttemberg, Germany)*. 2024, **11**(17),e2308051,
1214 **doi:10.1002/advs.202308051**.
- 1215 87. Wang J, Jansen JA, Yang F, Electrospraying: Possibilities and Challenges of Engineering
1216 Carriers for Biomedical Applications-A Mini Review, *Frontiers in chemistry*. 2019, **7**,258,
1217 **doi:10.3389/fchem.2019.00258**.



- 1218 88. Zhai M, Wu P, Liao Y, *et al.*, Polymer Microspheres and Their Application in Cancer Diagnosis
1219 and Treatment, *International journal of molecular sciences*. 2024, **25**(12),6556,
1220 **doi:10.3390/ijms25126556**.
- 1221 89. Strasdat B, Bunjes H, Development of a new approach to investigating the drug transfer from
1222 colloidal carrier systems applying lipid nanosuspension-containing alginate microbeads as
1223 acceptor, *International journal of pharmaceutics*. 2015, **489**(1-2),203-209,
1224 **doi:10.1016/j.ijpharm.2015.03.082**.
- 1225 90. Rouzé l'Alzit F, Cade R, Naveau A, *et al.*, Accuracy of commercial 3D printers for the
1226 fabrication of surgical guides in dental implantology, *Journal of dentistry*. 2022, **117**,103909,
1227 **doi:10.1016/j.jdent.2021.103909**.
- 1228 91. Xu X, Awad A, Robles-Martinez P, *et al.*, Vat photopolymerization 3D printing for advanced
1229 drug delivery and medical device applications, *Journal of controlled release : official journal*
1230 *of the Controlled Release Society*. 2021, **329**,743-757, **doi:10.1016/j.jconrel.2020.10.008**.
- 1231 92. Huang J, Yang R, Jiao J, *et al.*, A click chemistry-mediated all-peptide cell printing hydrogel
1232 platform for diabetic wound healing, *Nature communications*. 2023, **14**(1),7856,
1233 **doi:10.1038/s41467-023-43364-2**.
- 1234 93. Zub K, Hoeppener S, Schubert US, Inkjet Printing and 3D Printing Strategies for Biosensing,
1235 Analytical, and Diagnostic Applications, *Advanced materials (Deerfield Beach, Fla)*. 2022,
1236 **34**(31),e2105015, **doi:10.1002/adma.202105015**.
- 1237 94. Ricciotti L, Apicella A, Perrotta V, *et al.*, Geopolymer Materials for Extrusion-Based 3D-
1238 Printing: A Review, *Polymers*. 2023, **15**(24),4688, **doi:10.3390/polym15244688**.
- 1239 95. Kass LE, Nguyen J, Nanocarrier-hydrogel composite delivery systems for precision drug
1240 release, *Wiley interdisciplinary reviews Nanomedicine and nanobiotechnology*. 2022,
1241 **14**(2),e1756, **doi:10.1002/wnan.1756**.
- 1242 96. Liu J, Tagami T, Ozeki T, Fabrication of 3D-Printed Fish-Gelatin-Based Polymer Hydrogel
1243 Patches for Local Delivery of PEGylated Liposomal Doxorubicin, *Marine drugs*. 2020,
1244 **18**(6),325, **doi:10.3390/md18060325**.
- 1245 97. Eugster R, Ganguin AA, Seidi A, *et al.*, 3D printing injectable microbeads using a composite
1246 liposomal ink for local treatment of peritoneal diseases, *Drug delivery and translational*
1247 *research*. 2024, **14**(6),1567-1581, **doi:10.1007/s13346-023-01472-y**.
- 1248 98. Cohen S, Alonso MJ, Langer R, Novel approaches to controlled-release antigen delivery,
1249 *International journal of technology assessment in health care*. 1994, **10**(1),121-130,
1250 **doi:10.1017/s0266462300014045**.
- 1251 99. Li X, Naguib YW, Cui Z, In vivo distribution of zoledronic acid in a bisphosphonate-metal
1252 complex-based nanoparticle formulation synthesized by a reverse microemulsion method,
1253 *International journal of pharmaceutics*. 2017, **526**(1-2),69-76,
1254 **doi:10.1016/j.ijpharm.2017.04.053**.
- 1255 100. Zakharova A, Iqbal MW, Madadian E, *et al.*, Reverse Microemulsion-Synthesized High-
1256 Surface-Area Cu/ γ -Al(2)O(3) Catalyst for CO(2) Conversion via Reverse Water Gas Shift, *ACS*
1257 *applied materials & interfaces*. 2022, **14**(19),22082-22094, **doi:10.1021/acsami.2c01959**.
- 1258 101. Wang N, Zhao S, Tian X, *et al.*, Fabrication of microspheres containing coagulation factors by
1259 reverse microemulsion method for rapid hemostasis and wound healing, *Colloids and surfaces*
1260 *B, Biointerfaces*. 2022, **218**,112742, **doi:10.1016/j.colsurfb.2022.112742**.



- 1261 102. Han X, Sun M, Chen B, *et al.*, Lotus seedpod-inspired internal vascularized 3D printed scaffold
1262 for bone tissue repair, *Bioactive materials*. 2021, **6**(6),1639-1652,
1263 **doi:10.1016/j.bioactmat.2020.11.019**.
- 1264 103. Li G, Liu S, Chen Y, *et al.*, An injectable liposome-anchored teriparatide incorporated gallic
1265 acid-grafted gelatin hydrogel for osteoarthritis treatment, *Nature communications*. 2023,
1266 **14**(1),3159, **doi:10.1038/s41467-023-38597-0**.
- 1267 104. Karimi H, Rabbani S, Babadi D, *et al.*, Piperine liposome-embedded in hyaluronan hydrogel as
1268 an effective platform for prevention of postoperative peritoneal adhesion, *Journal of*
1269 *microencapsulation*. 2023, **40**(4),279-301, **doi:10.1080/02652048.2023.2194415**.
- 1270 105. Waghule T, Saha RN, Alexander A, *et al.*, Tailoring the multi-functional properties of
1271 phospholipids for simple to complex self-assemblies, *Journal of controlled release : official*
1272 *journal of the Controlled Release Society*. 2022, **349**,460-474,
1273 **doi:10.1016/j.jconrel.2022.07.014**.
- 1274 106. Gładkowski W, Włoch A, Pruchnik H, *et al.*, Acylglycerols of Myristic Acid as New Candidates
1275 for Effective Stigmasterol Delivery-Design, Synthesis, and the Influence on Physicochemical
1276 Properties of Liposomes, *Molecules (Basel, Switzerland)*. 2022, **27**(11),3406,
1277 **doi:10.3390/molecules27113406**.
- 1278 107. Zhang R, Han Y, McClements DJ, *et al.*, Production, Characterization, Delivery, and
1279 Cholesterol-Lowering Mechanism of Phytosterols: A Review, *Journal of agricultural and food*
1280 *chemistry*. 2022, **70**(8),2483-2494, **doi:10.1021/acs.jafc.1c07390**.
- 1281 108. Chen HW, Chen SD, Wu HT, *et al.*, Improvement in Curcumin's Stability and Release by
1282 Formulation in Flexible Nano-Liposomes, *Nanomaterials (Basel, Switzerland)*. 2024,
1283 **14**(22),1836, **doi:10.3390/nano14221836**.
- 1284 109. Lee JS, Hwang SY, Lee EK, Imaging-based analysis of liposome internalization to macrophage
1285 cells: Effects of liposome size and surface modification with PEG moiety, *Colloids and surfaces*
1286 *B, Biointerfaces*. 2015, **136**,786-790, **doi:10.1016/j.colsurfb.2015.10.029**.
- 1287 110. Gabizon AA, Shmeeda H, Zalipsky S, Pros and cons of the liposome platform in cancer drug
1288 targeting, *Journal of liposome research*. 2006, **16**(3),175-183,
1289 **doi:10.1080/08982100600848769**.
- 1290 111. Liu J, Du C, Chen H, *et al.*, Nano-Micron Combined Hydrogel Microspheres: Novel Answer
1291 for Minimal Invasive Biomedical Applications, *Macromolecular rapid communications*. 2024,
1292 **45**(11),e2300670, **doi:10.1002/marc.202300670**.
- 1293 112. Xeroudaki M, Rafat M, Moustardas P, *et al.*, A double-crosslinked nanocellulose-reinforced
1294 dexamethasone-loaded collagen hydrogel for corneal application and sustained anti-
1295 inflammatory activity, *Acta biomaterialia*. 2023, **172**,234-248,
1296 **doi:10.1016/j.actbio.2023.10.020**.
- 1297 113. Du AW, Stenzel MH, Drug carriers for the delivery of therapeutic peptides, *Biomacromolecules*.
1298 2014, **15**(4),1097-1114, **doi:10.1021/bm500169p**.
- 1299 114. Wang Z, Liu Z, Wang S, *et al.*, Implantation of hydrogel-liposome nanoplatfrom inhibits
1300 glioblastoma relapse by inducing ferroptosis, *Asian journal of pharmaceutical sciences*. 2023,
1301 **18**(3),100800, **doi:10.1016/j.ajps.2023.100800**.
- 1302 115. Guimarães D, Cavaco-Paulo A, Nogueira E, Design of liposomes as drug delivery system for
1303 therapeutic applications, *International journal of pharmaceutics*. 2021, **601**,120571,
1304 **doi:10.1016/j.ijpharm.2021.120571**.



- 1305 116. Lei Y, Wang Y, Shen J, *et al.*, Injectable hydrogel microspheres with self-renewable hydration
1306 layers alleviate osteoarthritis, *Science advances*. 2022, **8**(5),eabl6449,
1307 **doi:10.1126/sciadv.abl6449**.
- 1308 117. Chen K, Wang F, Ding R, *et al.*, Adhesive and Injectable Hydrogel Microspheres for Inner Ear
1309 Treatment, *Small (Weinheim an der Bergstrasse, Germany)*. 2022, **18**(36),e2106591,
1310 **doi:10.1002/sml.202106591**.
- 1311 118. Zhou Y, He X, Zhang W, *et al.*, Cell-recruited microspheres for OA treatment by dual-
1312 modulating inflammatory and chondrocyte metabolism, *Materials today Bio*. 2024, **27**,101127,
1313 **doi:10.1016/j.mtbio.2024.101127**.
- 1314 119. Ali SMA, Khan J, Shahid R, *et al.*, Chitosan-carrageenan microbeads containing nano-
1315 encapsulated curcumin: Nano-in-micro hydrogels as alternative-therapeutics for resistant
1316 pathogens associated with chronic wounds, *International journal of biological macromolecules*.
1317 2024, **278**(Pt 4),134841, **doi:10.1016/j.ijbiomac.2024.134841**.
- 1318 120. Xiong W, Han Z, Ding SL, *et al.*, In Situ Remodeling of Efferocytosis via Lesion-Localized
1319 Microspheres to Reverse Cartilage Senescence, *Advanced science (Weinheim, Baden-
1320 Wurttemberg, Germany)*. 2024, **11**(19),e2400345, **doi:10.1002/advs.202400345**.
- 1321 121. Liu A, He M, Liu C, *et al.*, Prevention of Hypercholesterolemia with "Liposomes in
1322 Microspheres" Composite Carriers: A Promising Approach for Intestinal-Targeted Oral
1323 Delivery of Astaxanthin, *Journal of agricultural and food chemistry*. 2024, **72**(12),6118-6132,
1324 **doi:10.1021/acs.jafc.3c08697**.
- 1325 122. Qu X, Xie Z, Zhang J, *et al.*, Regulating Mitochondrial Aging via Targeting the Gut-Bone Axis
1326 in BMSCs With Oral Hydrogel Microspheres to Inhibit Bone Loss, *Small (Weinheim an der
1327 Bergstrasse, Germany)*. 2024,e2409936, **doi:10.1002/sml.202409936**.
- 1328 123. Amin M, Lammers T, Ten Hagen TLM, Temperature-sensitive polymers to promote heat-
1329 triggered drug release from liposomes: Towards bypassing EPR, *Advanced drug delivery
1330 reviews*. 2022, **189**,114503, **doi:10.1016/j.addr.2022.114503**.
- 1331 124. Zhao C, Tian S, Liu Q, *et al.*, Biodegradable nanofibrous temperature-responsive gelling
1332 microspheres for heart regeneration, *Advanced functional materials*. 2020, **30**(21),200776,
1333 **doi:10.1002/adfm.202000776**.
- 1334 125. Li H, Li X, Shi X, *et al.*, Effects of magnetic dihydroartemisinin nano-liposome in inhibiting
1335 the proliferation of head and neck squamous cell carcinomas, *Phytomedicine : international
1336 journal of phytotherapy and phytopharmacology*. 2019, **56**,215-228,
1337 **doi:10.1016/j.phymed.2018.11.007**.
- 1338 126. Rodkate N, Rutnakornpituk M, Multi-responsive magnetic microsphere of poly(N-
1339 isopropylacrylamide)/carboxymethylchitosan hydrogel for drug controlled release,
1340 *Carbohydrate polymers*. 2016, **151**,251-259, **doi:10.1016/j.carbpol.2016.05.081**.
- 1341 127. Sonju JJ, Dahal A, Singh SS, *et al.*, A pH-sensitive liposome formulation of a peptidomimetic-
1342 Dox conjugate for targeting HER2 + cancer, *International journal of pharmaceutics*. 2022,
1343 **612**,121364, **doi:10.1016/j.ijpharm.2021.121364**.
- 1344 128. Kureha T, Aoki D, Hiroshige S, *et al.*, Decoupled Thermo- and pH-Responsive Hydrogel
1345 Microspheres Cross-Linked by Rotaxane Networks, *Angewandte Chemie (International ed in
1346 English)*. 2017, **56**(48),15393-15396, **doi:10.1002/anie.201709633**.



- 1347 129. Fu S, Chang L, Liu S, *et al.*, Temperature sensitive liposome based cancer nanomedicine enables
 1348 tumour lymph node immune microenvironment remodelling, *Nature communications*. 2023,
 1349 **14**(1),2248, doi:10.1038/s41467-023-38014-6.
- 1350 130. Huang H, Qi X, Chen Y, *et al.*, Thermo-sensitive hydrogels for delivering biotherapeutic
 1351 molecules: A review, *Saudi pharmaceutical journal : SPJ : the official publication of the Saudi*
 1352 *Pharmaceutical Society*. 2019, **27**(7),990-999, doi:10.1016/j.jsps.2019.08.001.
- 1353 131. Dwivedi P, Kiran S, Han S, *et al.*, Magnetic Targeting and Ultrasound Activation of Liposome-
 1354 Microbubble Conjugate for Enhanced Delivery of Anticancer Therapies, *ACS applied materials*
 1355 *& interfaces*. 2020, **12**(21),23737-23751, doi:10.1021/acsami.0c05308.
- 1356 132. Zhang Y, Xue Q, Liu J, *et al.*, Magnetic bead-liposome hybrids enable sensitive and portable
 1357 detection of DNA methyltransferase activity using personal glucose meter, *Biosensors &*
 1358 *bioelectronics*. 2017, **87**,537-544, doi:10.1016/j.bios.2016.08.103.
- 1359 133. Yao J, Feng X, Dai X, *et al.*, TMZ magnetic temperature-sensitive liposomes-mediated
 1360 magnetothermal chemotherapy induces pyroptosis in glioblastoma, *Nanomedicine :*
 1361 *nanotechnology, biology, and medicine*. 2022, **43**,102554, doi:10.1016/j.nano.2022.102554.
- 1362 134. Ulker D, Ozyurt R, Erkasap N, *et al.*, Magnetic Targeting of 5-Fluorouracil-Loaded Liposome-
 1363 Nanogels for In Vivo Breast Cancer Therapy and the Cytotoxic Effects on Liver and Kidney,
 1364 *AAPS PharmSciTech*. 2022, **23**(8),289, doi:10.1208/s12249-022-02438-y.
- 1365 135. Alawak M, Dayyih AA, Awak I, *et al.*, Magnetic Thermosensitive Liposomes Loaded with
 1366 Doxorubicin, *Methods in molecular biology (Clifton, NJ)*. 2023, **2622**,103-119,
 1367 doi:10.1007/978-1-0716-2954-3_9.
- 1368 136. Abri Aghdam M, Bagheri R, Mosafer J, *et al.*, Recent advances on thermosensitive and pH-
 1369 sensitive liposomes employed in controlled release, *Journal of controlled release : official*
 1370 *journal of the Controlled Release Society*. 2019, **315**,1-22, doi:10.1016/j.jconrel.2019.09.018.
- 1371 137. Ding H, Tan P, Fu S, *et al.*, Preparation and application of pH-responsive drug delivery systems,
 1372 *Journal of controlled release : official journal of the Controlled Release Society*. 2022, **348**,206-
 1373 238, doi:10.1016/j.jconrel.2022.05.056.
- 1374 138. Shao XR, Wei XQ, Zhang S, *et al.*, Effects of Micro-environmental pH of Liposome on
 1375 Chemical Stability of Loaded Drug, *Nanoscale research letters*. 2017, **12**(1),504,
 1376 doi:10.1186/s11671-017-2256-9.
- 1377 139. Aundhia C, Parmar G, Talele C, *et al.*, Light Sensitive Liposomes: A Novel Strategy for
 1378 Targeted Drug Delivery, *Pharmaceutical nanotechnology*. 2024,41-54,
 1379 doi:10.2174/0122117385271651231228073850.
- 1380 140. Li Q, Li W, Di H, *et al.*, A photosensitive liposome with NIR light triggered doxorubicin release
 1381 as a combined photodynamic-chemo therapy system, *Journal of controlled release : official*
 1382 *journal of the Controlled Release Society*. 2018, **277**,114-125,
 1383 doi:10.1016/j.jconrel.2018.02.001.
- 1384 141. Enzian P, Schell C, Link A, *et al.*, Optically Controlled Drug Release from Light-Sensitive
 1385 Liposomes with the New Photosensitizer 5,10-DiOH, *Molecular pharmaceuticals*. 2020,
 1386 **17**(8),2779-2788, doi:10.1021/acs.molpharmaceut.9b01173.
- 1387 142. Raman R, Hua T, Gwynne D, *et al.*, Light-degradable hydrogels as dynamic triggers for
 1388 gastrointestinal applications, *Science advances*. 2020, **6**(3),eaay0065,
 1389 doi:10.1126/sciadv.aay0065.



- 1390 143. Wang Z, Fu L, Liu D, *et al.*, Controllable Preparation and Research Progress of Photosensitive
 1391 Antibacterial Complex Hydrogels, *Gels (Basel, Switzerland)*. 2023, **9**(7),571,
 1392 **doi:10.3390/gels9070571**.
- 1393 144. Annabi N, Tamayol A, Uquillas JA, *et al.*, 25th anniversary article: Rational design and
 1394 applications of hydrogels in regenerative medicine, *Advanced materials (Deerfield Beach, Fla)*.
 1395 2014, **26**(1),85-123, **doi:10.1002/adma.201303233**.
- 1396 145. Pourbadiei B, Adlsadabad SY, Rahbariasr N, *et al.*, Synthesis and characterization of dual
 1397 light/temperature-responsive supramolecular injectable hydrogel based on host-guest
 1398 interaction between azobenzene and starch-grafted β -cyclodextrin: Melanoma therapy with
 1399 paclitaxel, *Carbohydrate polymers*. 2023, **313**,120667, **doi:10.1016/j.carbpol.2023.120667**.
- 1400 146. Paszko E, Senge MO, Immunoliposomes, *Current medicinal chemistry*. 2012, **19**(31),5239-
 1401 5277, **doi:10.2174/092986712803833362**.
- 1402 147. Tenchov R, Bird R, Curtze AE, *et al.*, Lipid Nanoparticles—From Liposomes to mRNA Vaccine
 1403 Delivery, a Landscape of Research Diversity and Advancement, *ACS nano*. 2021,
 1404 **15**(11),16982-17015, **doi:10.1021/acsnano.1c04996**.
- 1405 148. Rahman MM, Wang J, Wang G, *et al.*, Chimeric nanobody-decorated liposomes by self-
 1406 assembly, *Nature nanotechnology*. 2024, **19**(6),818-824, **doi:10.1038/s41565-024-01620-6**.
- 1407 149. Bosco G, Mszar R, Piro S, *et al.*, Cardiovascular Risk Estimation and Stratification Among
 1408 Individuals with Hypercholesterolemia, *Current atherosclerosis reports*. 2024, **26**(9),537-548,
 1409 **doi:10.1007/s11883-024-01225-3**.
- 1410 150. Paz Ocaranza M, Riquelme JA, García L, *et al.*, Counter-regulatory renin-angiotensin system
 1411 in cardiovascular disease, *Nature reviews Cardiology*. 2020, **17**(2),116-129,
 1412 **doi:10.1038/s41569-019-0244-8**.
- 1413 151. Jiang J, Xiao F, Yang L, *et al.*, Protective effect of astaxanthin on chronic prostatitis/chronic
 1414 pelvic pain syndrome in rat through modulating NF- κ B signaling pathway, *Translational*
 1415 *andrology and urology*. 2024, **13**(9),1971-1983, **doi:10.21037/tau-24-190**.
- 1416 152. Zheng Z, Lei C, Liu H, *et al.*, A ROS-Responsive Liposomal Composite Hydrogel Integrating
 1417 Improved Mitochondrial Function and Pro-Angiogenesis for Efficient Treatment of Myocardial
 1418 Infarction, *Advanced healthcare materials*. 2022, **11**(19),e2200990,
 1419 **doi:10.1002/adhm.202200990**.
- 1420 153. Lei Y, Wang X, Liao J, *et al.*, Shear-responsive boundary-lubricated hydrogels attenuate
 1421 osteoarthritis, *Bioactive materials*. 2022, **16**,472-484, **doi:10.1016/j.bioactmat.2022.02.016**.
- 1422 154. Namangkalakul W, Nagai S, Jin C, *et al.*, Augmented effect of fibroblast growth factor 18 in
 1423 bone morphogenetic protein 2-induced calvarial bone healing by activation of CCL2/CCR2 axis
 1424 on M2 macrophage polarization, *Journal of tissue engineering*. 2023, **14**,1-19,
 1425 **doi:10.1177/20417314231187960**.
- 1426 155. Wang Y, Pu C, Han Z, *et al.*, In Situ Profferocytosis Microspheres as Macrophage Polarity
 1427 Converters Accelerate Osteoarthritis Treatment, *Small (Weinheim an der Bergstrasse,*
 1428 *Germany)*. 2025,e2405236, **doi:10.1002/smll.202405236**.
- 1429 156. Jahanmard F, Khodaei A, Flapper J, *et al.*, Osteoimmunomodulatory GelMA/liposome coatings
 1430 to promote bone regeneration of orthopedic implants, *Journal of controlled release : official*
 1431 *journal of the Controlled Release Society*. 2023, **358**,667-680,
 1432 **doi:10.1016/j.jconrel.2023.05.022**.



- 1433 157. Zhi Y, Che J, Zhu H, *et al.*, Glycyrrhetic Acid Liposomes Encapsulated Microcapsules from
1434 Microfluidic Electrospray for Inflammatory Wound Healing, 2023, **33**(43),2304353,
1435 **doi:10.1002/adfm.202304353**.
- 1436 158. Armstrong DG, Tan TW, Boulton AJM, *et al.*, Diabetic Foot Ulcers: A Review, *Jama*. 2023,
1437 **330**(1),62-75, **doi:10.1001/jama.2023.10578**.
- 1438 159. Qi X, Xiang Y, Li Y, *et al.*, An ATP-activated spatiotemporally controlled hydrogel prodrug
1439 system for treating multidrug-resistant bacteria-infected pressure ulcers, *Bioactive materials*.
1440 2025, **45**,301-321, **doi:10.1016/j.bioactmat.2024.11.029**.
- 1441 160. Shi C, Zhang Y, Wu G, *et al.*, Hyaluronic Acid-Based Reactive Oxygen Species-Responsive
1442 Multifunctional Injectable Hydrogel Platform Accelerating Diabetic Wound Healing, *Advanced*
1443 *healthcare materials*. 2024, **13**(4),e2302626, **doi:10.1002/adhm.202302626**.
- 1444 161. Wu X, Ding C, Liu X, *et al.*, The role of phlorizin liposome-embedded oxidized sodium
1445 alginate/carboxymethyl chitosan in diabetic wound healing, *International journal of biological*
1446 *macromolecules*. 2024, **279**(Pt 3),135324, **doi:10.1016/j.ijbiomac.2024.135324**.
- 1447 162. Zhai T, Ai P, Tang Z, *et al.*, Intratympanic injection of hydrogel nanodrug for the prevention
1448 and treatment of sensorineural hearing loss, *Journal of otology*. 2023, **18**(4),235-239,
1449 **doi:10.1016/j.joto.2023.09.005**.
- 1450 163. Meric-Bernstam F, Larkin J, Tabernero J, *et al.*, Enhancing anti-tumour efficacy with
1451 immunotherapy combinations, *Lancet (London, England)*. 2021, **397**(10278),1010-1022,
1452 **doi:10.1016/s0140-6736(20)32598-8**.
- 1453 164. Yan YF, Li XL, Zeng LZ, *et al.*, Antitumor Cream: Transdermal Hydrogel Containing
1454 Liposome-Encapsulated Ruthenium Complex for Infrared-Controlled Multimodal Synergistic
1455 Therapy, *Advanced healthcare materials*. 2024,e2403563, **doi:10.1002/adhm.202403563**.
- 1456 165. Gao C, Cheng K, Li Y, *et al.*, Injectable Immunotherapeutic Hydrogel Containing RNA-Loaded
1457 Lipid Nanoparticles Reshapes Tumor Microenvironment for Pancreatic Cancer Therapy, *Nano*
1458 *letters*. 2022, **22**(22),8801-8809, **doi:10.1021/acs.nanolett.2c01994**.
- 1459 166. Wang SW, Gao C, Zheng YM, *et al.*, Current applications and future perspective of
1460 CRISPR/Cas9 gene editing in cancer, *Molecular cancer*. 2022, **21**(1),57, **doi:10.1186/s12943-022-01518-8**.
- 1461 167. Chen Z, Liu F, Chen Y, *et al.*, Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene
1462 Therapy via Liposome-Templated Hydrogel Nanoparticles, *Advanced functional materials*.
1463 2017, **27**(46),1703036, **doi:10.1002/adfm.201703036**.
- 1464 168. Gordon S, Young K, Wilson R, *et al.*, Chitosan hydrogels containing liposomes and cubosomes
1465 as particulate sustained release vaccine delivery systems, *Journal of liposome research*. 2012,
1466 **22**(3),193-204, **doi:10.3109/08982104.2011.637502**.
- 1467 169. Lima PHC, Butera AP, Cabeça LF, *et al.*, Liposome surface modification by phospholipid
1468 chemical reactions, *Chemistry and physics of lipids*. 2021, **237**,105084,
1469 **doi:10.1016/j.chemphyslip.2021.105084**.
- 1470 170. Moriyama J, Yoshimoto M, Efficient Entrapment of Carbonic Anhydrase in Alginate Hydrogels
1471 Using Liposomes for Continuous-Flow Catalytic Reactions, *ACS omega*. 2021, **6**(9),6368-6378,
1472 **doi:10.1021/acsomega.0c06299**.
- 1473 171. He H, Lu Y, Qi J, *et al.*, Adapting liposomes for oral drug delivery, *Acta pharmaceutica Sinica*
1474 *B*. 2019, **9**(1),36-48, **doi:10.1016/j.apsb.2018.06.005**.
- 1475



- 1476 172. Chen L, Lin S, Sun N, Food gel-based systems for efficient delivery of bioactive ingredients, design to application, *Critical reviews in food science and nutrition*. 2024, **64**(33),13193-13211, **doi:10.1080/10408398.2023.2262578**. [View Article Online](#)
DOI: 10.1039/D5TB01369K
- 1477
- 1478
- 1479 173. Chang H, Cai F, Zhang Y, *et al.*, Silencing Gene-Engineered Injectable Hydrogel Microsphere for Regulation of Extracellular Matrix Metabolism Balance, *Small methods*. 2022, **6**(4),e2101201, **doi:10.1002/smt.202101201**.
- 1480
- 1481
- 1482 174. Teng Y, Chi J, Huang J, *et al.*, Hydrogel toughening resets biomedical application boundaries, *Progress in Polymer Science*. 2025, **161**,101929, **doi:10.1016/j.progpolymsci.2025.101929**.
- 1483
- 1484 175. Wang C, Lan X, Zhu L, *et al.*, Construction Strategy of Functionalized Liposomes and Multidimensional Application, *Small (Weinheim an der Bergstrasse, Germany)*. 2024, **20**(25),2309031, **doi:10.1002/smll.202309031**.
- 1485
- 1486
- 1487 176. Li H, Yu L, Li Z, *et al.*, A Narrative Review of Bioactive Hydrogel Microspheres: Ingredients, Modifications, Fabrications, Biological Functions, and Applications, *Small (Weinheim an der Bergstrasse, Germany)*. 2025, **21**(25),2500426, **doi:10.1002/smll.202500426**.
- 1488
- 1489
- 1490



Data availability

View Article Online
DOI: 10.1039/D5TB01369K

The data and information presented in this review are based on previously published studies, which are cited throughout the article.

